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Prevention and Treatment of Tuberculosis
Among Patients Infected
with Human Immunodeficiency Virus:
Principles of Therapy and Revised Recommendations
Summary
These guidelines update previous CDC recommendations for the diagnosis,
treatment, and prevention of tuberculosis (TB) among adults and children co-
infected with human immunodeficiency virus (HIV) in the United States. The
most notable changes in these guidelines reflect both the findings of clinical tri-
als that evaluated new drug regimens for treating and preventing TB among
HIV-infected persons and recent advances in the use of antiretroviral therapy. In
September 1997, when CDC convened a meeting of expert consultants to dis-
cuss current information about HIV-related TB, special emphasis was given to
issues related to coadministration of TB therapy and antiretroviral therapy and
how to translate this information into management guidelines. Thus, these
guidelines are based on the following scientific principles:
• Early diagnosis and effective treatment of TB among HIV-infected patients are
critical for curing TB, minimizing the negative effects of TB on the course of
HIV, and interrupting the transmission of Mycobacterium tuberculosis to other
persons in the community.
• All HIV-infected persons at risk for infection with M. tuberculosis must be care-
fully evaluated and, if indicated, administered therapy to prevent the
progression of latent infection to active TB disease and avoid the complica-
tions associated with HIV-related TB.
• All HIV-infected patients undergoing treatment for TB should be evaluated for
antiretroviral therapy, because most patients with HIV-related TB are candi-
dates for concurrent administration of antituberculosis and antiretroviral drug
therapies. However, the use of rifampin with protease inhibitors or non-
nucleoside reverse transcriptase inhibitors is contraindicated.
Ideally, the management of TB among HIV-infected patients taking anti-
retroviral drugs requires a) directly observed therapy, b) availability of
experienced and coordinated TB/HIV care givers, and in most situations, c) use
of a TB treatment regimen that includes rifabutin instead of rifampin. Because
alternatives to the use of rifampin for antituberculosis treatment are now avail-
able, the previously recommended practice of stopping protease inhibitor
therapy to allow the use of rifampin for TB treatment is no longer recommended
for patients with HIV-related TB. The use of rifabutin-containing antituberculosis
regimens should always include an assessment of the patient’s response to
treatment to decide the appropriate duration of therapy (i.e., 6 months or
9 months). Physicians and patients also should be aware that paradoxical reac-
tions might occur during the course of TB treatment when antiretroviral therapy
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restores immune function. Adding to CDC’s current recommendations for ad-
ministering isoniazid preventive therapy to HIV-infected persons with positive
tuberculin skin tests and to HIV-infected persons who were exposed to patients
with infectious TB, this report also describes in detail the use of new short-
course (i.e., 2 months) multidrug regimens (e.g., a rifamycin, such as rifampin or
rifabutin, combined with pyrazinamide) to prevent TB in persons with HIV infec-
tion. A continuing education component for U.S. physicians and nurses is
included.
INTRODUCTION
These guidelines update previous CDC recommendations for treating and prevent-
ing active tuberculosis (TB) among adults and children coinfected with human
immunodeficiency virus (HIV) (1–3 ). The most notable changes in these guidelines
reflect both the recent advances in the use of antiretroviral therapy and the findings of
clinical trials that evaluated new drug regimens for the treatment and prevention of TB
among HIV-infected persons. Antiretroviral therapy is discussed in the context of TB
treatment only; more detailed information about antiretroviral therapy is published
elsewhere (4 ).
In September 1997, CDC convened a meeting of expert consultants who reviewed
and considered background information about HIV-related TB in the United States and
the scientific principles of therapy for both diseases (Part I of this report). The consult-
ants then used this review as the basis for updating the recommendations for
HIV-infected patients with TB (Part II). During their review of the scientific principles of
therapy, the expert consultants focused on epidemiologic and clinical interactions
between Mycobacterium tuberculosis infection and HIV infection, considering the
frequency of coexisting TB and HIV infection and rates of drug-resistant TB among
patients infected with HIV in the United States; the copathogenicity of TB and HIV
disease; the potential for a poorer outcome of TB therapy and paradoxical reactions to
TB treatment among HIV-infected patients; drug interactions between rifampin used
for TB therapy and agents commonly used in antiretroviral therapy; use of TB treat-
ment regimens that do not contain rifampin; and results of clinical trials of therapies
to prevent TB among HIV-infected persons. Thus, in addition to CDC’s current recom-
mendations, these new guidelines include information about the following topics:
• directly observed therapy for all patients with HIV-related TB;
• rifabutin-containing antituberculosis regimens (or a streptomycin-based alterna-
tive regimen that does not contain rifamycin) for treating TB among patients
taking antiretroviral drugs that have interactions with rifampin;
• monitoring responses to antituberculosis treatment to decide about the appro-
priate duration of TB therapy;
• occurrence and management of paradoxical reactions during TB treatment,
when immune function is restored because of antiretroviral therapy;
• use of 9 months of isoniazid daily or twice weekly for the treatment of M. tuber-
culosis  infection;
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• short-course multidrug therapy for latent M. tuberculosis  infection; and
• special considerations that apply to children and pregnant women with HIV-
related TB.
Health-care professionals need to be familiar with these new guidelines to ensure
the use of the most effective management strategies for TB patients infected with HIV,
while concurrently promoting optimal antiretroviral therapy for these patients. To help
clinicians make informed treatment decisions based on the most current research
results, the expert consultants have given each recommendation an evidence-based
rating similar to the ratings used in previously issued guidelines (4,5 ). However, these
recommendations are not intended to substitute for the judgment of an expert physi-
cian. When possible, the treatment of TB in HIV-infected persons should be directed by
(or done in consultation with) a physician with extensive experience in the care of
patients with TB and HIV disease. The implementation of these recommendations will
help prevent cases of drug-resistant TB, reduce TB treatment failures, and diminish
the adverse effects that TB has on HIV replication. Moreover, these guidelines will
contribute to efforts to control TB and eliminate it from the United States by minimiz-
ing the likelihood of M. tuberculosis transmission, which will prevent the occurrence
of new cases of TB. 
In future years, health-care professionals can expect changes in the recommenda-
tions regarding the therapeutic options used to prevent and treat TB among patients
infected with HIV. These changes will reflect the availability of new antiretroviral and
antituberculosis agents, new information about existing agents, and subsequent
changes in CDC’s guidelines for the use of antiretroviral therapy for persons infected
with HIV. Multiple copies of this report and all updates are available from the Office of
Communications, National Center for HIV, STD, and TB Prevention, CDC, 1600 Clifton
Road, Mail Stop E-06, Atlanta, GA 30333. The report also is posted on the CDC Division
of TB Elimination Internet website at <http://www.cdc.gov/nchstp/tb> and the MMWR
website at <http://www.cdc.gov/epo/mmwr/mmwr.html>. Readers should consult
these sources regularly for updates in the guidelines. 
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PART I. BACKGROUND AND SCIENTIFIC RATIONALE
Frequency of Coexisting TB and HIV Infection and Disease
in the United States
In the United States, epidemiologic evidence indicates that the HIV epidemic con-
tributed substantially to the increased numbers of TB cases in the late 1980s and early
1990s (6,7 ). Overlap between the acquired immunodeficiency syndrome (AIDS) and
TB epidemics continues to result in increases in TB morbidity. Analysis of national
HIV-related TB surveillance data is limited by incomplete reporting of HIV status for
persons with TB. As an alternative, state health department personnel have compared
TB and AIDS registries to help estimate the proportion of persons reported with TB
who are also infected with HIV. In the most recent comparison conducted by the
50 states and Puerto Rico, 14% of persons with TB in 1993–1994 (27% among those
aged 25–44 years) also appeared in the AIDS registry (8 ). This proportion of TB pa-
tients with AIDS is believed to be a minimum estimate for the United States and might
represent an increase in the proportion of TB patients identified as having TB and
AIDS in 1990 (9%) (6 ). During 1993–1994, most persons with TB and AIDS (80%) were
found in eight reporting areas: New York City, California, Florida, Georgia, Illinois, New
Jersey, New York, and Texas (8 ). 
In prospective epidemiologic studies, investigators have estimated that the annual
rate of TB disease among untreated, tuberculin skin-test (TST)-positive, HIV-infected
persons in the United States ranges from 1.7 to 7.9 TB cases per 100 person-years
(Table 1) (9–11 ). The variability observed in these studies mirrors the differences in TB
prevalence observed for different U.S. populations (i.e., the highest case rate was
found in a study of a New York City population of intravenous drug users at a time
when the incidence of TB was high and increasing [9 ]; and the lowest case rate was
evident in a community-based cohort of persons enrolled in a study of the pulmonary
complications of HIV infection at a time and in a population in which the incidence of
TB was relatively low [11 ]). However, in all of these studies, the rate of TB disease
among HIV-infected, TST-positive persons was approximately 4–26 times higher than
the rate among comparable HIV-infected, TST-negative persons, and it was approxi-
mately 200–800 times higher than the rate of TB estimated for the U.S. population
overall (0.01%) (12 ). Therefore, activities to control and eliminate TB in the United
States must include aggressive efforts to identify HIV-infected persons with latent
TABLE 1. Annual rates* of tuberculosis among persons with human imunodeficiency





with negative TSTs Rate ratio
New York City
Selwyn et al., 1989 (9 )
7.9 0.3 26.3
San Francisco
Daley et al., 1998 (10 )
5.0 1.0  5.0
Multiple sites
Markowitz et al., 1997 (11 )
 East Coast 4.6 1.3  3.5
 West/Midwest 1.7 0.2  8.5
 All sites 4.5 0.4 11.3
*Cases per 100 person-years.
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TB infection and to provide them with therapy to prevent progression to active TB
disease.
Rates of Drug-Resistant TB Among HIV-Infected Persons
in the United States
Resistance to antituberculosis drugs is an important consideration for some HIV-
infected persons with TB. According to the results of a study of TB cases reported to
CDC from 1993 through 1996, the risk of drug-resistant TB was higher among persons
with known HIV infection compared with others (13 ). During this 4-year period,
among U.S.-born persons aged 25–44 years with TB, HIV test results were reported as
positive for 32% of persons, negative for 23%, and unknown for 45%. Using univariate
analysis that excluded patients known to have had a previous episode of TB, investi-
gators found that patients known to be HIV seropositive had a significantly higher rate
of resistance to all first-line antituberculosis drugs, compared with HIV-seronegative
patients and patients with unknown HIV serostatus (Table 2). Moreover, using a multi-
variate model that included age, history of previous TB, birth country, residence in
New York City, and race/ethnicity, the investigators confirmed HIV-positive serostatus
as a risk factor for resistance to at least isoniazid, for both isoniazid and rifampin resis-
tance (multidrug-resistant [MDR] TB) and for rifampin monoresistance (TB resistant to
rifampin only). In some areas of the United States with a low level of occurrence of
MDR TB, however, differences in MDR TB related to HIV status have not been found
(8 ). Reasons for the increased risk for TB drug resistance among HIV-seropositive per-
sons might reflect a higher proportion of TB disease resulting from recently acquired
M. tuberculosis infection (14,15 ) and thus an increased risk of disease caused by
drug-resistant strains in areas with high community and institutional transmission of
drug-resistant strains of M. tuberculosis (16 ). Several well-described outbreaks of
TABLE 2. Percentage of tuberculosis (TB) patients* with drug-resistant isolates,† by









Isoniazid 11.3 5.5 6.8
Rifampin  8.9 1.6 2.5
Pyrazinamide  5.1 1.8 2.2
Streptomycin  6.7 4.1 5.0
Ethambutol  3.9 1.5 2.0
Isoniazid and rifampin  6.2 1.3 1.5
Rifampin only¶  2.4 0.2 0.8
*Patients were born in the United States, were aged 22–44 years, and were not known to have
had a previous episode of TB. All TB cases reported from California are included in the HIV-
unknown category.
†The patient’s Mycobacterium tuberculosis  isolate had resistance to at least the specified drug
but may have had resistance to other drugs as well.
§The differences in drug-resistance rates among patients with TB known to be HIV-seropositive,
compared with those known to be HIV-seronegative or of unknown status, are statistically
significant (Chi-square test statistic, p<0.05).
¶These figures were calculated for patients with M. tuberculosis  isolates tested for isoniazid
and rifampin always and streptomycin sometimes. Monoresistant isolates were resistant to
rifampin but susceptible to the other first-line drugs tested.
Source: CDC, National Tuberculosis Surveillance System.
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nosocomially transmitted MDR TB, primarily affecting persons with AIDS, support this
association (17–21 ). 
In the past decade, reports have increased of TB caused by strains of M. tuberculo-
sis resistant to rifampin only, and growing evidence has indicated that this rare event
is associated with HIV coinfection (22–32 ). In retrospective studies, nonadherence
with TB therapy has been associated with acquired rifampin monoresistance (22–24 );
and among a small number of patients, the use of rifabutin as prophylaxis for Myco-
bacterium avium complex was associated with the development of rifamycin
resistance (31 ). However, the occurrence of TB relapse with acquired rifampin
monoresistance also has been documented among patients with TB who initially had
rifampin-susceptible isolates and who were treated with a rifampin-containing TB
regimen by directly observed therapy (DOT) (30,32 ). The mechanisms involved in the
development of acquired rifampin monoresistance are not clearly understood but
could involve the persistence of actively multiplying mycobacteria in patients with
severe cellular immunodeficiency, selective antituberculosis drug malabsorption, and
inadequate tissue penetration of drugs.
Thus, of critical importance for HIV-infected persons is implementation of TB
prevention and control strategies such as a) appropriate use of therapy for latent
M. tuberculosis infection, b) early diagnosis and effective treatment of active TB (i.e.,
administering four-drug antituberculosis regimens by DOT to all coinfected patients),
and c) prompt compliance with requirements for reporting TB cases and drug-suscep-
tibility test results. Implementing these strategies for persons coinfected with HIV will
not only help reduce new cases of TB in general; it also could decrease further trans-
mission of drug-resistant strains and new cases of drug-resistant TB.
Copathogenicity of TB and HIV Disease
Human immunodeficiency virus type 1 (HIV-1) and M. tuberculosis are two intra-
cellular pathogens that interact at the population, clinical, and cellular levels. Initial
studies of HIV-1 and TB emphasized the impact of HIV-1 on the natural progression of
TB, but mounting immunologic and virologic evidence now indicates that the host
immune response to M. tuberculosis enhances HIV replication and might accelerate
the natural progression of HIV infection (33 ). Therefore, the interaction between these
two pathogens has important implications for the prevention and treatment of TB
among HIV-infected persons. Studies of the immune response in persons with TB dis-
ease support the biologic plausibility of copathogenesis in dually infected persons.
The initial interaction between the host immune system and M. tuberculosis occurs in
the alveolar macrophages that present mycobacterial antigens to antigen-specific
CD4+ T cells (34 ). These T cells release interferon-gamma, a cytokine that acts at the
cellular level to activate macrophages and enhance their ability to contain mycobacte-
rial infection. The activated macrophages also release proinflammatory cytokines,
such as tumor necrosis factor and interleukin (IL)-1, cytokines that enhance viral repli-
cation in monocyte cell lines in vitro (35–38 ). The mycobacteria and their products
also enhance viral replication by inducing nuclear factor kappa-B, the cellular factor
that binds to promoter regions of HIV (39,40 ).
When TB disease develops in an HIV-infected person, the prognosis is often poor,
though it depends on the person’s degree of immunosuppression and response to
appropriate antituberculosis therapy (41–43 ). The 1-year mortality rate for treated,
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HIV-related tuberculosis ranges from 20% to 35% and shows little variation between
cohorts from industrialized and developing countries (44–49 ). The observed mortality
rate for HIV-infected persons with TB is approximately four times greater than the rate
for TB patients not infected with HIV (44,46,49,50 ). Although the cause of death in the
initial period of therapy can be TB (46 ), death after the induction phase of antituber-
culosis therapy usually is attributed to complications of HIV other than TB (45,51,52 ).
Epidemiologic data suggest that active TB accelerates the natural progression of HIV
infection. In a retrospective cohort study of HIV-infected women from Zaire, investiga-
tors estimated the relative risk of death to be 2.7 among women with active TB
compared with those without TB (53 ). In a retrospective cohort study of HIV-infected
subjects from the United States, active TB was associated with an increased risk for
opportunistic infections and death (54 ). The risk of death, or hazard rate, for persons
with HIV-related TB follows a bimodal distribution, peaking within the first 3 months
of antituberculosis therapy and then again after 1 year (48 ); the reasons for this distri-
bution are not clear but might relate to the impact of TB on HIV disease progression.
The observation that active TB increases deaths associated with HIV infection has
been corroborated in studies of three independent cohorts in Europe (55–57 ).
Early in the HIV epidemic, researchers postulated that the immune activation re-
sulting from concurrent infection with parasitic or bacterial pathogens might alter the
natural progression of HIV infection (58 ). Subsequent observations have demon-
strated that immune activation from TB enhances both systemic and local HIV
replication. In some patients with active TB, the plasma HIV RNA level rises substan-
tially before TB is diagnosed (59 ). Moreover, TB treatment alone leads to reductions
in the viral load in these dually infected patients. TB and HIV also interact in the lungs,
the site of primary infection with M. tuberculosis. In a recently published study of HIV-
infected patients with TB, researchers found that the viral load was higher in the
bronchoalveolar lavage fluid from the affected versus the unaffected lung and was
correlated with levels of tumor necrosis factor in bronchoalveolar fluid (60 ). Re-
searchers used V3 loop viral sequences to construct a phylogenetic tree and observed
that the HIV quasispecies from the affected lung differed from those in the plasma
within the same patient. These data suggest that pulmonary TB might act as a potent
stimulus for the cellular-level replication of HIV. In summary, recent research findings
have improved clinicians’ understanding of how HIV affects the natural progression of
TB and how TB affects the clinical course of HIV disease, and these findings support
the recommendation for prevention, early recognition, and effective treatment for
both diseases.
TB Therapy Outcomes Among Patients with HIV-Related TB
Among patients treated for TB, early clinical response to therapy and the time
in which M. tuberculosis sputum cultures convert from positive to negative appear
to be similar for those with HIV infection and those without HIV infection (30,61,62 ).
However, the data are less clear about whether rates of TB relapse (recurrence of TB
following successful completion of treatment) differ among patients with or without
HIV infection (63 ). Current CDC and American Thoracic Society guidelines recom-
mend a 6-month treatment regimen for drug-susceptible TB disease for patients
coinfected with HIV (2 ) but suggest prolonged treatment for patients who have a
delayed clinical and bacteriologic response to antituberculosis therapy. Some experts
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have suggested that to ensure an optimal antituberculosis treatment outcome, all
patients with HIV-related TB should be treated with a longer course of therapy (i.e.,
9 months), regardless of evidence of early response to therapy (64,65 ).
To make a recommendation on duration of therapy for HIV-related TB, expert con-
sultants at the September 1997 CDC meeting considered the results of prospective
studies that ascertained the posttreatment relapse rate following 6-month TB therapy
regimens among patients with HIV infection (Table 3) (29,30,49,66,67 ). Differences in
the study designs, including those pertaining to eligibility for enrollment in the study
and to the definition of TB relapse, limited the analysis of combined results from the
five studies. Despite this limitation, the expert consultants were able to make the fol-
lowing observations: a) the studies had a posttreatment follow-up duration that
ranged from 8 to 22 months (median duration: 18 months); b) in three studies
(30,49,67 ), investigators found that 6-month TB regimens were associated with a
clinically acceptable (≤5.4%) TB relapse rate; and c) in two studies (29,66 ), researchers
TABLE 3. Posttreatment relapse rates and CD4+ T-cell counts among patients enrolled
in prospective studies of 6-month* tuberculosis (TB) treatment regimens, by human
immunodeficiency virus (HIV) serostatus — Continued
Location






Perriens et al., 1995 (66 )
HIV positive
(n=124)
9.0 338 cells/µL3 • All cases of TB











not assessed by DNA
fingerprinting.
Côte d’Ivoire
Kassim et al., 1995 (49 )
HIV-1 positive
(n=106)













• Relapse vs. reinfection
not assessed by DNA
fingerprinting.
Haiti
Chaisson et al., 1996 (67 )
HIV positive
(n=177)











• Relapse vs. reinfection
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found a high (≥9%) TB relapse rate associated with the use of 6-month TB regimens.
In the Zaire study (66 ), TB patients coinfected with HIV had almost twofold higher
posttreatment relapse rates than patients not infected with HIV who received the same
TB treatment regimen; however, the authors did not investigate whether the relapses
were the result of a recurrence of disease with the same strain of M. tuberculosis or
reinfection (new disease) with a different strain. In the other study (29 ), which
enrolled HIV-seropositive patients from 21 different sites in the United States, in all
three patients who relapsed, the strain of M. tuberculosis isolated during the relapse
episode matched, by DNA fingerprint, the strain of M. tuberculosis that was isolated
during the initial episode of TB; this finding ruled out the possibility of reinfection.
The expert consultants who reviewed the available data agreed that short-course
(i.e., 6-month) regimens should be used for the treatment of HIV-related pansuscep-
tible TB (i.e., susceptible to all first-line antituberculosis drugs) in the United States,
where patients are usually treated with DOT and where response to antituberculosis
TABLE 3. Posttreatment relapse rates and CD4+ T-cell counts among patients enrolled
in prospective studies of 6-month* tuberculosis (TB) treatment regimens, by human
immunodeficiency virus (HIV) serostatus — Continued
Location






U.S. Public Health Service
Rifapentine Trial Group et
al., 1998 (29 )
HIV positive
(n=30)
10 137 cells/µL3 • All cases of TB



























by culture. Of the
two relapse isolates,
one matched and





* TB regimens mostly consisted of a 2-month, four-drug (isoniazid, rifampin, pyrazinamide, and ethambutol)
daily induction regimen followed by a continuation regimen of 4-month intermittent isoniazid and rifampin.
The exceptions are that a) ethambutol was not used during the induction phase in Côte d’Ivoire, and b) half
of patients in one of the U.S. studies (30 ) received levofloxacin in addition to the other four drugs during
the induction phase. During the continuation phase, patients in Côte d’Ivoire received drugs daily, patients
in Haiti received drugs three times a week, and patients in all other studies received drugs twice a week.
†
Also in this study, 51 comparable patients with HIV-related TB were randomly assigned to a treatment arm
in which the duration of the continuation phase was prolonged from 4 months to 7 months. The culture-
confirmed posttreatment relapse rate (2%) in this study arm was not significantly different from the rate in
the 6-month study arm (p=1.00); however, an isolate was not available for DNA fingerprinting.
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drugs can be monitored. This approach limits the use of lengthier multidrug antituber-
culosis therapies to the minimum possible number of patients with TB and HIV
disease. Some experts believe the risk of TB treatment failure is increased among
patients with advanced HIV-related immunosuppression and therefore advocate
greater caution (or longer duration of therapy) when treating such patients for TB.
The available data do not permit CDC to make a definitive recommendation regarding
this issue. However, the experts recommended that clinicians treating TB in patients
with HIV infection should consider the factors that increase a person’s risk for a poor
clinical outcome (e.g., lack of adherence to TB therapy, delayed conversion of M. tu-
berculosis sputum cultures from positive to negative, and delayed clinical response)
when deciding the total duration of TB therapy.
Paradoxical Reactions Associated with Initiation of Antiretroviral Therapy
During the Course of TB Therapy
The temporary exacerbation of TB symptoms and lesions after initiation of anti-
tuberculosis therapy — known as a paradoxical reaction — has been described as a
rare occurrence (68–74 ) attributed to causes such as recovery of the patient’s delayed
hypersensitivity response and an increase in exposure and reaction to mycobacterial
antigens after bactericidal antituberculosis therapy is initiated (75 ). Recently, a similar
phenomenon was reported among patients with HIV-related TB (76 ). These reactions
appear to be related more often to the concurrent administration of antiretroviral and
antituberculosis therapy and occur with greater frequency than do paradoxical reac-
tions associated primarily with the administration of antituberculosis therapy. Patients
with paradoxical reactions can have hectic fevers, lymphadenopathy (sometimes
severe), worsening of chest radiographic manifestations of TB (e.g., miliary infiltrates,
pleural effusions), and worsening of original tuberculous lesions (e.g., cutaneous and
peritoneal). However, these reactions are not associated with changes in M. tubercu-
losis bacteriology (i.e., no change from negative to positive culture and smear), and
patients generally feel well and have no signs of toxicity.
In a prospective study, paradoxical reactions were more common among 33 pa-
tients with HIV-related TB who received TB treatment and combination antiretroviral
therapy (36%) than among 55 patients not infected with HIV who received antitubercu-
losis drugs alone (2%) and among 28 HIV-infected patients (historical control patients
during pre-zidovudine era) who received antituberculosis drugs alone (7%) (76 ). Fur-
thermore, among patients treated for both diseases, the paradoxical reactions were
more temporally related to the initiation of combination antiretroviral therapy (mean
+/- standard deviation [SD]: 15 +/- 11 days afterward) than to the initiation of antituber-
culosis treatment (mean SD: 109 +/- 72 days afterward). Researchers investigated
potential causes for these symptoms and lesions (i.e., TB treatment failure, antituber-
culosis drug resistance, nonadherence with TB therapy, drug fever, development of
conditions not related to TB or HIV) but considered such causes unlikely because
these evaluations produced negative results, and TB was cured in patients who
remained on unmodified antituberculosis regimens. Among patients in this study who
received combination antiretroviral therapy, which usually included a protease inhibi-
tor, the paradoxical reactions corresponded with a concurrent drop in HIV viral loads
after antiretroviral therapy began and, in all but one patient, occurred while peripheral
blood CD4+ T-cell counts were <200 cells/µL (76 ). In the historical control group (i.e.,
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patients who were treated for TB but not for HIV), two (7%) of the 28 patients had a
paradoxical reaction after antituberculosis therapy was initiated. This finding indicates
that treatment of TB alone might sometimes decrease HIV viral load substantially and
improve immune function (40,59,68,76 ).
After reviewing information about paradoxical reactions occurring during the
course of TB therapy, expert consultants at the September 1997 CDC meeting con-
cluded that exacerbation of TB signs and symptoms in patients with HIV-related TB
can occur soon after combination antiretroviral therapy is initiated. Clinicians should
always conduct a thorough investigation to eliminate other etiologies before making
a diagnosis of paradoxical treatment reaction. For patients with paradoxical reactions,
rarely are changes in antituberculosis or antiretroviral therapy needed. If the lym-
phadenopathy or other lesions are severe, one option is to continue with appropriate
antituberculosis therapy and administer short-term steroids that suppress the en-
hanced immune response. 
In the prospective study (76 ), despite having low CD4+ T-cell counts, six (86%) of
seven TB patients who were initially tuberculin skin-test (TST)-negative had positive
TST results after combination antiretroviral therapy was started. The reaction sizes of
postantiretroviral TSTs ranged from 7 to 67 mm of induration. Clinicians must be
aware of the potential public health and clinical implications of restored TST reactivity
among persons who have not been diagnosed with active TB but who might be lat-
ently infected with M. tuberculosis. Persons previously known to have negative TST
results might benefit from repeat tuberculin testing if they have evidence of restored
immune function after antiretroviral therapy is initiated, because TB preventive ther-
apy is recommended for TST-positive HIV-infected persons.
Considerations for TB Therapy for HIV-Infected Patients Treated with
Antiretroviral Agents
Drug Interactions Between Rifamycins Used for TB Therapy and Antiretroviral Drugs
Used for HIV Therapy
Widely used antiretroviral drugs available in the United States include protease
inhibitors (saquinavir, indinavir, ritonavir, and nelfinavir) and nonnucleoside reverse
transcriptase inhibitors (NNRTIs) (nevirapine, delavirdine, and efavirenz). Protease
inhibitors and NNRTIs have substantive interactions with the rifamycins (rifampin,
rifabutin, and rifapentine) used to treat mycobacterial infections (3,77 ). These drug
interactions principally result from changes in the metabolism of the antiretroviral
agents and the rifamycins secondary to induction or inhibition of the hepatic
cytochrome CYP450 enzyme system (78,79 ). Rifamycin-related CYP450 induction de-
creases the blood levels of drugs metabolized by CYP450. For example, if protease
inhibitors are administered with rifampin (a potent CYP450 inducer), blood concentra-
tions of the protease inhibitors (all of which are metabolized by CYP450) decrease
markedly, and most likely the antiretroviral activity of these agents declines as well.
Conversely, if ritonavir (a potent CYP450 inhibitor) is administered with rifabutin,
blood concentrations of rifabutin increase markedly, and most likely rifabutin toxicity
increases as well.
Of the available rifamycins, rifampin is the most potent CYP450 inducer; rifabutin
has substantially less activity as an inducer; and rifapentine, a newer rifamycin, has
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intermediate activity as an inducer (80–82 ). The four currently approved protease
inhibitors and amprenavir (141W94, an investigational agent in Phase III clinical trials)
are all, in differing degrees, inhibitors of CYP450 (83,84 ). The rank order of the agents
in terms of potency in inhibiting CYP450 is ritonavir (the most potent); amprenavir,
indinavir, and nelfinavir (with approximately equal potencies); and saquinavir (the
least potent). The magnitude of the effects of coadministering rifamycins and pro-
tease inhibitors has been evaluated in limited pharmacokinetic studies (Table 4)
(85–91 ). The three approved NNRTIs have  diverse effects on CYP450: nevirapine is an
inducer, delavirdine is an inhibitor, and efavirenz is both an inducer and an inhibitor.
The magnitude of the effects of coadministering rifamycins and NNRTIs has also been
evaluated in pharmacokinetic studies or has been predicted on the basis of what is
known about their potential for inducing or inhibiting CYP450 (Table 5) (92–96 ).
In contrast to the protease inhibitors and the NNRTIs, the other class of antiretro-
viral agents available, nucleoside reverse transcriptase inhibitors (NRTIs) (zidovudine,
didanosine, zalcitabine, stavudine, and lamivudine) are not metabolized by CYP450.
Rifampin (and to a lesser degree, rifabutin) increases the glucuronidation of zi-
dovudine and thus slightly decreases the serum concentration of zidovudine
(97–100 ). The effect of this interaction probably is not clinically important, and the
concurrent use of NRTIs and rifamycins is not contraindicated (77 ). Also, no contrain-
dication exists for the use of NRTIs, NNRTIs, and protease inhibitors with isoniazid,
pyrazinamide, ethambutol, or streptomycin. These first-line antituberculosis medica-
tions, in contrast to the rifamycins, are not CYP450 inducers.
Coadministration of Antituberculosis and Antiretroviral Therapies
According to 1998 U.S. Department of Health and Human Services guidelines on
the use of antiretroviral agents among HIV-infected adults and adolescents (4 ), to im-
prove the length and quality of patients’ lives, all persons with symptomatic HIV
infection should be offered antiretroviral therapy. HIV-infected patients with TB fall in
this category. When used appropriately, combinations of potent antiretroviral agents
can effect prolonged suppression of HIV replication and reduce the inherent tendency
of HIV to generate drug-resistant viral strains. However, as antiretroviral therapeutic
regimens have become increasingly effective, they also have become increasingly
complex in themselves as well as in the problems they cause for the treatment of
other HIV-associated diseases.
At present, regimens that include two NRTIs combined with a potent protease in-
hibitor (or, as an alternative, combined with an NNRTI) are the preferred choice for
combination antiretroviral therapy for the majority of patients. Each of the antiretrovi-
ral drug combination regimens must be used according to optimum schedules and
doses (4 ) because the potential for resistant mutations of HIV decreases if serum con-
centrations of the multiple antiretroviral drugs are maintained steadily. Because
rifampin markedly lowers the blood levels of these drugs and is likely to result in
suboptimal antiretroviral therapy, the use of rifampin to treat active TB in a patient
who is taking a protease inhibitor or an NNRTI is always contraindicated. Rifabutin is
a less potent inducer of the CPY450 cytochrome enzymes than is rifampin and, when
used in appropriately modified doses, might not be associated with a clinically signifi-
cant reduction of protease inhibitors or nevirapine (Table 6). Thus, the substitution of
rifabutin for rifampin in TB treatment regimens has been proposed as a practical
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TABLE 4. Effects of coadministering rifamycins and protease inhibitors (PIs) on the
systemic exposure (area-under-the-concentration-time curve [AUC]) of each drug*
PI and source
Rifampin (RIF) Rifabutin (RFB)
RIF’s effect on PI PI’s effect on RIF RFB’s effect on PI PI’s effect on RFB
Saquinavir†
Sahai et al., 1996 (85 )
80% decrease Data not 
reported 
45% decrease Data not
reported
Ritonavir










Group, 1996 (88 )
92% decrease Data not
reported




82% decrease Data not
reported




Sadler et al., 1998 (91 )
81% decrease Unchanged 14% decrease 200% increase
¶
* Effects are expressed as a percentage change in AUC of the concomitant treatment relative to that of the
drug-alone treatment. No data are available regarding the magnitude of these bidirectional interactions




Data from only two subjects.
¶
Percentages reflect increases in minimum concentrations; values for the AUC are not reported.
TABLE 5. Known and predicted effects of coadministering rifamycins and
nonnucleoside reverse transcriptase inhibitors (NNRTIs) on the systemic exposure
(area-under-the-concentration-time curve [AUC]) of each drug*
NNRTI and source
Rifampin (RIF) Rifabutin (RFB)
RIF’s effect       
on NNRTI       
NNRTI’s effect
on RIF
RFB’s effect       
on NNRTI       
NNRTI’s effect    









Borin et al., 1997 (93 )
Borin et al., 1997 (94 )
Cox et al., 1998 (95 )
96% decrease Unchanged
†











* Effects are expressed as a percentage change in AUC of the concomitant treatment relative to that of the
drug-alone treatment. No data are available regarding the magnitude of these bidirectional interactions
when rifamycins are administered two or three times a week instead of daily.
†
Predicted effect based on knowledge of metabolic pathways for the two drugs.
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TABLE 6. Feasibility of using different antiretroviral drugs and rifabutin
Antiretroviral
agent





Probably Use of the soft-gel formulation (Fortovase) in
higher-than-usual doses might allow adequate serum
concentrations of this drug despite concurrent use of
rifabutin.* However, the pharmacokinetic data for this
combination are limited in comparison with other
protease inhibitors. Because of the expected low
bioavailability of the hard-gel formulation (Invirase) the
concurrent use of this agent with rifabutin is not
recommended.
Ritonavir No Ritonavir increases concentrations of rifabutin by 35-fold
and results in increased rates of toxicity (arthralgia,
uveitis, skin discoloration, and leukopenia). These
adverse events have been noted in studies of high-dose
rifabutin therapy, when rifabutin is administered with
clarithromycin (another CYP450 inhibitor) — an indication
that these events might result from high serum
concentrations of rifabutin.
Indinavir Yes Data from drug interaction studies (unpublished report,
Merck Research Laboratories, West Point, PA, 1998)
suggest that the dose of indinavir should be increased
from 800 mg every 8 hours to 1,200 mg every 8 hours if
used in combination with rifabutin.*
Nelfinavir Yes Some clinical experts suggest that the dose of nelfinavir
should be increased from 750 mg three times a day to
1,000 mg three times a day if used in combination with
rifabutin.*
Amprenavir Probably The drug interactions between amprenavir and rifabutin
(and thus potential for rifabutin toxicity) are reported to
be similar to those of ritonavir with rifabutin. However,
potential advantages of using this combination are that a)
rifabutin has a minimal effect on reducing the levels of
amprenavir and b) even though it has not been studied,
rifabutin toxicity is not expected if the daily dose of
rifabutin is reduced when used in combination with
amprenavir.
NRTIs† Yes Not expected to have clinically significant interaction.
Nevirapine Yes Not known whether nevirapine or rifabutin dose
adjustments are necessary when these drugs are used
together.*
Delavirdine No Not recommended on the basis of marked decreases in
concentrations of delavirdine when administered with
rifamycins.
Efavirenz Probably Newly approved agent. Preliminary drug interaction
studies suggest that when rifabutin is used concurrently
with efavirenz, the dose of rifabutin for both daily and
twice weekly administration should be increased from
300 mg to 450 mg.
*Daily dose of rifabutin should be reduced from 300 mg to 150 mg if used in combination with
amprenavir, nelfinavir, or indinavir. It is unknown whether the dose of rifabutin should be
reduced if used in combination with saquinavir (Fortovase) or nevirapine.
†Nucleoside reverse transcriptase inhibitiors, including zidovudine, didanosine, zalcitabine, sta-
vudine, and lamivudine.
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choice for patients who are also undergoing therapy with protease inhibitors (with the
exception of ritonavir [86,87,101–103 ] or hard-gel capsule saquinavir [Invirase (85 )])
or with the NNRTIs nevirapine or efavirenz (but not delavirdine [93,94 ]). Currently,
more clinical and pharmacokinetic data are available on the use of indinavir or nelfi-
navir with rifabutin than on the use of amprenavir or soft-gel saquinavir (Fortovase)
with rifabutin. Rifapentine is not recommended as a substitute for rifampin because
its safety and effectiveness have not been established for the treatment of patients
with HIV-related TB. As an alternative to the use of rifamycin for the treatment of TB,
the use of streptomycin-based regimens that do not contain rifamycin can be consid-
ered for the treatment of TB in patients undergoing antiretroviral therapy with
protease inhibitors or NNRTIs.
Use of Rifabutin-Based Regimens for the Treatment of HIV-Related TB
At present, TB drug regimens that include rifabutin instead of rifampin appear to
offer the best alternative for the treatment of active TB among patients taking anti-
retroviral therapies that include protease inhibitors or NNRTIs. This recommendation
is based on findings from studies of equivalent in vitro antituberculosis activity of
rifabutin and rifampin (104,105 ) and the results of three clinical trials (106–108 ).
These trials demonstrated that 6-month rifabutin-containing regimens (at a daily dose
of either 150 mg or 300 mg) were as effective and as safe as similar control regimens
containing rifampin for the treatment of TB (Table 7). The smallest (n=49) of these
TABLE 7. Results from clinical trials* that compared rifabutin (RFB) with rifampin (RIF)
























NH, RFB150, PZA, 
EMB; daily/

























































* Comparison regimens included INH, PZA, and EMB with the same doses and intervals of administration as in
the study regimens; however, comparison regimens included RIF (600 mg daily or twice a week) instead of
RFB (150 mg daily, 300 mg daily, or 300 mg twice a week).
†
All patients were known to be HIV-1 seropositive.
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three trials was conducted in Uganda (108 ) and is the only one to include HIV-
coinfected patients (who were not undergoing antiretroviral therapy at the time of
the study). This study indicated that 81% of patients taking a TB treatment regimen
containing daily rifabutin converted their sputum from M. tuberculosis positive to
negative after 2 months of treatment, compared with a 48% sputum conversion rate
among patients taking a TB regimen containing daily rifampin (p<0.05). However,
when the researchers controlled for differences in baseline characteristics (a greater
proportion of patients in the rifampin group had cavitary disease), they found no dif-
ference in the time to sputum conversion between the two study groups. 
Studies are under way to evaluate the use of rifabutin administered daily (at a dose
of 150 mg) or twice a week (at a dose of 300 mg) for the treatment of TB in HIV-infected
patients who take protease inhibitors. Physicians at a state tuberculosis hospital in
Florida have treated or consulted on the treatment of approximately 30 HIV-infected
patients who received a protease inhibitor while undergoing treatment for TB with
rifabutin. Patients have been treated for TB primarily with administration of rifabutin
(150 mg daily) as part of four-drug therapy for 2–4 weeks, followed by rifabutin
(300 mg twice weekly) as part of four-drug therapy to complete 8 weeks of induction,
and then a continuation phase consisting of twice-weekly isoniazid and rifabutin
(300 mg) to complete 6 months of treatment. To date, patients treated with this regi-
men have not experienced clinically significant increases in rifabutin serum levels,
have had a minimal incidence of adverse reactions from rifabutin (one patient devel-
oped a case of uveitis), and have had a good clinical response to TB and HIV therapies.
Approximately 80% of the patients attained sputum conversion by the second month
of treatment, most have attained and maintained suppression of HIV replication, and
no TB relapses have occurred with up to 1 year of posttreatment follow-up (David
Ashkin, M.D., and Masahiro Narita, M.D., A.G. Holley State Tuberculosis Hospital, Lan-
tana, Florida, personal communication, 1998).
In previous reports, CDC and the American Thoracic Society jointly recommended
the use of rifampin-containing short-course regimens for the initial treatment of HIV-
related TB (2 ). The inclusion of rifampin in regimens to treat TB was supported by
data collected from approximately 90 controlled clinical trials conducted from 1968 to
1988 (109 ). Excluding rifampin from the TB treatment regimen was not recommended
because regimens not containing rifampin a) had not been proven to have acceptable
efficacy (i.e., have been associated with higher rates of TB treatment failure and death
and with slower bacteriologic responses to therapy leading to potential increases in
the likelihood of M. tuberculosis transmission) and b) require prolonging duration of
therapy from 6 months to 12–15 months. Presently, available data suggest that rifabu-
tin in short-course (i.e., 6 months) multidrug regimens to treat TB provides the same
benefits as the use of rifampin. Three additional reasons support the use of rifabutin
for treating HIV-related TB: a) observations suggest that rifabutin might be more reli-
ably absorbed than rifampin in patients with advanced HIV disease (110,111 ); b) the
use of rifabutin appears to have been better tolerated in patients with rifampin-
induced hepatotoxicity (David Ashkin, M.D., and Masahiro Narita, M.D., A.G. Holley
State Tuberculosis Hospital, Lantana, Florida, personal communication, 1998); and
c) the use of rifabutin might lessen the possibility of interactions with other medica-
tions commonly prescribed for patients with HIV infection (e.g., azole antifungal
drugs, anticonvulsant agents, and methadone) (77 ).
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Use of Alternative TB Treatment Regimens that Contain Minimal or No Rifamycin
TB treatment regimens that contain no rifamycins have been proposed as an alter-
native for patients who take protease inhibitors or NNRTIs. Several clinical trials
conducted in Hong Kong and Africa by the British Medical Research Council and
published from 1974 through 1984 provide information about nonrifamycin and
minimal-rifamycin regimens for the treatment of TB in patients who were not likely to
be infected with HIV (Table 8) (112–115 ). Most of these studies demonstrated high
relapse rates when regimens not containing streptomycin were used and when the
duration of therapy was less than 9 months. However, in a large (n=404) randomized
controlled clinical trial in Hong Kong that evaluated the use of six TB treatment regi-
mens consisting of streptomycin, isoniazid, and pyrazinamide either daily, three times
a week, or two times a week for 6 or 9 months (112 ), almost all patients treated with
any of the study regimens achieved rapid sputum conversions (86%–94% of patients
converted within 3 months of therapy). In this study, the 30-month posttreatment
follow-up relapse rates were high (18%–24%) among patients treated with 6-month
regimens, but the relapse rates among patients treated with 9-month regimens (5%–
6%) were similar to the relapse rates expected following the use of rifampin-based TB
treatments. Thus, the expert consultants who developed these guidelines concluded
that treatment of TB without rifamycin always requires longer-duration (at least
9 months) regimens that include streptomycin (or an injectable antituberculosis drug
TABLE 8. Posttreatment relapse rates associated with tuberculosis treatment
regimens containing minimal or no rifampin among patients not known to be
coinfected with human immunodeficiency virus
Location and source Treatment regimens
Posttreatment
relapses (%)
Hong Kong • 6 months of SM, INH, PZA; daily 18
Hong Kong Chest Service/British
Medical Research Council, 1977 (112 )
• 6 months of SM, INH, PZA;
three times a week 24
• 6 months of SM, INH, PZA;
two times a week 21
• 9 months of SM, INH, PZA; daily  5
• 9 months of SM, INH, PZA;
three times a week  6
• 9 months of SM, INH, PZA;
two times a week  6
Algeria
Algerian Working Group/British Medical
Research Council, 1984 (113 )
• 2 months of INH, RIF, PZA, EMB; daily/
4 months of INH, RIF; daily  3
17
East Africa • 6 months of SM, INH, RIF; daily  2
East African/British Medical Research
Council, 1974 (114 )
• 6 months of SM, INH, PZA; daily 11
29
East Africa
East African/British Medical Research
Council, 1980 (115 )
• 1 month of SM, INH, RIF, PZA; daily/
5 months of SM, INH, PZA;
two times a week  9
• 1 month of SM, INH, RIF, PZA; daily/
7 months of SM, INH, PZA;
two times a week  2
• 6 months of SM, INH; daily
• 1 month of SM, INH, EMB; daily/
11 months of INH, EMB; daily
EMB=ethambutol; INH=isoniazid; PZA=pyrazinamide; RIF=rifampin; SM=streptomycin.
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such as capreomycin, amikacin, or kanamycin) (63 ). However, these TB regimens
have not been studied among patients with HIV infection.
Streptomycin is highly bactericidal against M. tuberculosis, but it is rarely used
in the United States to treat drug-susceptible TB because of problems associated with
its administration by injection that can be intensified in patients with low body mass
or wasting and because of potential ototoxicity and nephrotoxicity. The associated
potential toxicities and increased duration of therapy and the patient’s difficulty in
adhering to an injectable-drug–based TB regimen can compromise the effectiveness
of streptomycin-based TB regimens, and these limitations should be considered by
physicians and patients.
Treatment of Latent M. tuberculosis Infection in Patients with HIV Infection
Scientific Rationale
Preventive therapy for TB is essential to controlling and eliminating TB in the
United States (116,117 ). Treatment for HIV-infected persons who are latently infected
with M. tuberculosis  is an important part of this strategy and is also an important
personal health intervention because of the serious complications associated with
active TB in HIV-infected persons (118–120 ). Expert consultants attending the Sep-
tember 1997 CDC meeting and additional consultants attending a September 1998
meeting sponsored by the American Thoracic Society and CDC considered findings
from multiple studies (121–130 ) before developing recommendations about the opti-
mal duration of isoniazid preventive therapy regimens; frequency of administration
(intermittency) of preventive therapy; new short-course multidrug regimens; and pre-
ventive therapy for anergic HIV-infected adults with a high risk of M. tuberculosis
infection. 
A key difference in most preventive therapy trials conducted before and after the
beginning of the HIV epidemic is that the earlier trials focused on 12-month regimens
of isoniazid, whereas five of seven trials (122–126 ) conducted in HIV-infected popula-
tions assessed 6-month regimens of isoniazid (Table 9). Four of these 6-month
isoniazid regimens (122-125 ) were chosen for study on the basis of the operational
feasibility of providing therapy in countries with limited resources where preventive
therapy programs were not available; the fifth study (126 ), a U.S. trial conducted
among anergic patients, used a 6-month regimen because of the absence of previous
data about optimal duration of therapy for TST-negative, HIV-infected patients.
Despite these variations, the expert consultants concluded that the findings from
these different preventive therapy studies should apply to most persons with latent
M. tuberculosis infection, regardless of their HIV serostatus, because similar levels of
protection have been observed when identical preventive therapy regimens have
been administered to persons infected with HIV and those not infected.
Optimal Duration of Isoniazid Regimens for Treatment of Latent
M. tuberculosis Infection
The American Thoracic Society and CDC have previously recommended a regimen
of 12 months of isoniazid alone for treatment of latent M. tuberculosis infection in
HIV-infected adults (2 ). The recommended duration of TB preventive therapy for
persons not infected with HIV was a minimum of 6 months. When considering the
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optimal duration of isoniazid preventive therapy, the consultants reviewed findings
from two studies conducted in populations not known to be infected with HIV
(128,129 ). One of these studies, a controlled trial conducted in seven European coun-
tries, compared the efficacy of three durations (3, 6, and 12 months) of isoniazid
preventive treatment for TST-positive persons with stable, fibrotic lesions on chest
radiographs (128 ). In this study, compliant patients who received medication for
TABLE 9. Results from studies of tuberculosis (TB) preventive therapy among persons














Pape et al., 1993 (121 ) TST positive (n=25) 12 months of placebo; daily 10.0 5.8 (1.2–28.7)
TST positive (n=38) 12 months of INH; daily  1.7 1          
TST negative (n=35) 12 months of placebo; daily  5.7 1.8 (0.4–9.2) 
TST negative (n=20) 12 months of INH; daily  3.2 1          
Haiti 
Halsey et al., 1994 (122 ) TST positive (n=370) 6 months of INH;
two times a week
 1.7 1          
TST positive (n=380) 2 months of RIF, PZA;
two times a week
 1.8 1.1        
(CI not       
available) 
Uganda 
Whalen et al., 1997 (123 ) TST positive (n=464) 6 months of placebo; daily  3.4 1         
TST positive (n=536) 6 months of INH; daily  1.1 0.3 (0.1–0.8)
TST positive (n=556) 3 months of INH, RIF; daily  1.3 0.4 (0.2–0.9)
TST positive (n=462) 3 months of INH, RIF, PZA; daily  1.7 0.4 (0.2–0.9)
Anergic (n=323) 6 months of placebo; daily  3.1 1         
Anergic (n=395) 6 months of INH; daily  2.5 0.7 (0.3–1.9)
Zambia 
Mwinga et al.,
in press (124 )
TST positive (n=60) 6 months of placebo;
two times a week
 9.8 1          
TST positive (n=52) 6 months of INH;
two times a week
 2.3 0.3 (0.05–1.4)
TST positive (n=49) 3 months of RIF, PZA;
two times a week
 2.7 0.3 (0.05–1.4)
TST negative (n=166) 6 months of placebo;
two times a week
 3.1 1          
TST negative (n=178) 6 months of INH;
two times a week
 2.5  0.9 (0.31–2.4)
TST negative (n=173) 3 months of RIF, PZA;
two times a week
 3.8  1.3 (0.50–3.2)
Kenya 
Hawken et al., 1997 (125 ) TST positive (n=67) 6 months of placebo; daily  8.0 1         
TST positive (n=69) 6 months of INH; daily  5.6 0.6 (0.2–1.6)
TST negative (n=235) 6 months of placebo; daily  2.7 1         
TST negative (n=224) 6 months of INH; daily  3.3 1.2 (0.6–2.7)
United States 
Gordin et al., 1997 (126 ) Anergic (n=257) 6 months of placebo; daily  0.9 1         
Anergic (n=260) 6 months of INH; daily  0.4 0.5 (0.1–1.9)
United States, Haiti,
Mexico, and Brazil
Gordin et al., 1998 (127 ) TST positive (n=792) 12 months of INH; daily  1.2 1         
TST positive (n=791) 2 months of RIF, PZA; daily  1.2 1.0 (0.6–1.7)
CI=confidence interval; INH=isoniazid; PZA=pyrazinamide; RIF=rifampin.
TST=tuberculin skin test.
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12 months had better protection against TB (93%) than those who received medica-
tion for 6 months (69%). The other study was conducted among the Inuits in the Bethel
area of Alaska, where participants received 0–24 months of isoniazid preventive ther-
apy (129 ). In an assessment of observed posttherapy case rates of TB relative to the
amount of isoniazid ingested (expressed as a percentage of a 12-month regimen), re-
searchers found that higher amounts of therapy corresponded with lower TB rates
among participants who had received 0–9 months of isoniazid therapy; after 9 months
of therapy, participants had no additional benefits in terms of decreased TB case rates.
Four studies of HIV-infected persons have evaluated 6-month and 12-month regi-
mens of daily isoniazid (121,123,125,127 ). Both of the studies that evaluated a
6-month regimen included a placebo comparison group and demonstrated reductions
in the incidence of TB among persons in the treatment group — 70% in Uganda (123 )
and 75% in Kenya (125 ). A study of the 12-month regimen (121 ), which was con-
ducted in Haiti and also included a placebo comparison group, demonstrated an 83%
reduction in the incidence of TB among persons in the treatment group. A multicenter
trial conducted in the United States, Mexico, Brazil, and Haiti (127 ) demonstrated that
the magnitude of protection obtained from a regimen of isoniazid administered daily
for 12 months was similar to that obtained from a regimen of rifampin and pyrazi-
namide administered daily for 2 months. Isoniazid preventive therapy regimens of
6 and 12 months’ duration have not been compared with each other in the same study
conducted among HIV-infected persons. In summary, these data indicate that a) the
optimal duration of isoniazid preventive therapy should be >6 months to provide the
maximum degree of protection against TB; b) therapy for 9 months appears to be
sufficient; c) therapy for >12 months does not appear to provide additional protection.
Frequency of Administering Isoniazid Preventive Therapy 
Two clinical trials (122,124 ) have evaluated 6-month twice-weekly isoniazid regi-
mens for the prevention of active TB in HIV-infected persons (Table 9). Participants
enrolled in the twice-weekly 6-month isoniazid arm of a study conducted in Zambia
had a 40% reduction in the rate of TB compared with persons who took a placebo for
6 months (124 ). The findings of a trial conducted in Haiti (122 ) suggest that the mag-
nitude of protection obtained from isoniazid administered twice a week for 6 months
is equivalent to that obtained from rifampin and pyrazinamide regimens administered
twice a week for 2 months. Preventive therapy trials that include twice-weekly
isoniazid regimens for >6 months or comparisons of the same drugs administered
daily versus intermittently have not been conducted. However, in a Baltimore demon-
stration project in which isoniazid was administered twice a week (10–15 mg/kg, with
a maximum dose of 900 mg) to a cohort of injecting-drug users under directly
observed preventive therapy (DOPT), the findings support the efficacy of twice-weekly
isoniazid preventive therapy (130 ). Twice-weekly regimens with DOPT were used in
Baltimore because the project staff expected that supervised delivery of therapy
would enhance adherence with and completion of the preventive therapy regimen.
Thus, the available data suggest that the protection obtained from isoniazid preven-
tive therapy regimens should be the same whether the drug is administered daily or
twice a week. 
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Short-Course Multidrug Regimens for TB Preventive Therapy
Four clinical trials (122–124,127 ) conducted among HIV-infected populations have
evaluated courses of preventive therapy that are shorter than 6 months and that
include rifampin in combination with isoniazid or pyrazinamide (Table 9). The largest
and most recent of these trials was a multicenter, randomized TB prevention study
conducted from 1992 through 1998 (127 ). Researchers found identical rates of TB
(1.2 per 100 person-years) in two groups of TST-positive, HIV-infected persons: those
who primarily self-administered isoniazid daily for 12 months and those who primarily
self-administered rifampin and pyrazinamide daily for 2 months. Both study groups
had similar adverse events and mortality rates; persons taking rifampin and pyrazi-
namide for 2 months were significantly more likely (80%) to complete therapy than
were persons taking isoniazid for 12 months (68%) (p<0.001). Two other trials con-
ducted in Haiti and Zambia (122,124 ) have also evaluated regimens of rifampin and
pyrazinamide for the prevention of TB but have not included comparison arms of 12-
month isoniazid regimens. The study in Haiti (122 ) compared patients receiving
rifampin and pyrazinamide administered twice a week for 2 months with patients re-
ceiving isoniazid twice a week for 6 months; in both arms of the study, one of the
twice-weekly doses was administered by DOPT. Investigators observed no difference
in TB risk or mortality among participants enrolled in the two treatment arms (122 ).
The placebo-controlled trial in Zambia demonstrated comparable protection from
3 months of rifampin and pyrazinamide versus 6 months of isoniazid; both regimens
were self-administered twice a week (124 ). In the multicenter trial (127 ) and in the
Haiti and Zambia studies (122,124 ), regimens that included rifampin and pyrazi-
namide were well tolerated. In a study conducted in Uganda (123 ), investigators
observed no statistically significant reduction in TB rates but a high rate of toxicity and
drug intolerance among persons who took three drugs (isoniazid, rifampin, and pyraz-
inamide) daily for 3 months compared with persons who took a placebo (Table 9);
3 months of daily self-administered rifampin and isoniazid provided protection similar
to that of 6 months of daily self-administered isoniazid. Thus, short-course multidrug
regimens (i.e., two drugs for 2–3 months) have been shown to be effective for the
prevention of active TB in HIV-infected persons. The use of three drugs for preventive
therapy, however, can be associated with unacceptably high rates of toxicity, and the
use of a 3-month regimen of rifampin and isoniazid is not being considered for use in
the United States. Available data indicate that in the United States, a regimen of ri-
fampin and pyrazinamide administered daily for 2 months is a reasonable treatment
option for HIV-infected adults with latent M. tuberculosis infection. The available data
do not permit CDC to make a definitive statement regarding the intermittent (i.e., twice
a week) administration of a 2-month regimen of rifampin and pyrazinamide.
Preventive Therapy for Anergic HIV-Infected Adults with a High Risk of Latent
M. tuberculosis Infection
Isoniazid preventive therapy has not been found to be useful or cost-effective in
preventing TB when administered to anergic, HIV-infected persons (123,126 ) (Table 9).
The anergic subjects who received isoniazid in the Uganda trial had a statistically
insignificant (17%) reduction in the rate of TB (2.5 cases per 100 person-years) com-
pared with patients in the placebo group (3.1 cases per 100 person-years) (123 ).
Similarly, anergic HIV-infected persons with a high risk for tuberculous infection who
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were enrolled in a U.S. multicenter trial and treated with isoniazid daily for 6 months
had a rate of TB (0.4 cases per 100 person-years) that was 50% less than, but not
statistically different from, the rate observed among patients treated with placebo
(0.9 cases per 100 person-years) (126 ). In both of these studies, HIV-infected persons
with anergy tolerated isoniazid well, as suggested by the low rates of adverse reac-
tions and high rates of therapy completion. These study findings do not support the
routine use of preventive therapy in anergic, HIV-infected persons. Preventive therapy
for TST-negative, HIV-infected persons also has not been proven effective (121,124,
125 ) (Table 9); however, some experts recommend primary preventive therapy (to
prevent M. tuberculosis infection) for TST-negative or anergic HIV-infected residents
of institutions that pose an ongoing high risk for exposure to M. tuberculosis  (e.g.,
prisons, jails, homeless shelters).
Implications of Results of TB Preventive Therapy Trials
The effects of TB preventive therapy on mortality and progression of HIV infection
appear to be limited, with the exception that such therapy can protect against the
development of TB disease and its associated consequences. Moreover, the duration
of this protective effect has not been clearly established for HIV-infected persons.
Despite these limitations and uncertainties, preventive therapy is recommended be-
cause its benefits in preventing TB disease are thought to be greater than the risks of
serious treatment-related adverse events, and such therapy benefits society by help-
ing to prevent the spread of infection to other persons in the community.
The implementation of TB preventive therapy programs should be facilitated by the
use of newly recommended short-course multidrug regimens and twice-weekly
isoniazid regimens, especially among patients for whom DOPT is feasible. Because of
the drug interactions between rifampin and protease inhibitors or NNRTIs, the use of
shorter regimens containing rifampin is contraindicated for patients taking these anti-
retroviral drugs. Although preventive therapy trials evaluating rifabutin use among
TST-positive, HIV-infected persons have not been conducted, the expert consultants
reviewed available data and agreed that the use of rifabutin instead of rifampin is valid
on the basis of the same scientific principles that support the use of rifabutin for the
treatment of active TB.
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PART II. RECOMMENDATIONS
This section of the report provides clinicians with recommendations for diagnos-
ing, treating, and preventing TB among persons coinfected with HIV while con-
currently promoting optimal antiretroviral care for these patients. The recommenda-
tions reflect the current state of knowledge regarding the use of antiretroviral agents,
but this field of science is rapidly evolving. As new antiretroviral agents and new data
regarding existing agents alter therapeutic options and preferences for antiretroviral
therapy, these changes might affect future recommendations for the treatment of TB
infection and disease among patients coinfected with HIV and the treatment of HIV
infection among persons with TB. Expert consultants updated these recommenda-
tions after a September 1997 CDC meeting, where they reviewed and considered
available information about the scientific principles of therapy for TB and HIV.
To help clinicians make informed treatment decisions based on the most current
research results, the expert consultants have given the recommendations evidence-
based ratings (general recommendations have no rating). The ratings include a letter
and a Roman numeral (Table 10), similar to the ratings used in previously issued
guidelines (4,5 ). The letter indicates the strength of the recommendation, and the Ro-
man numeral indicates the nature of the evidence supporting the recommendation.
Thus, clinicians can use the ratings to differentiate between recommendations based
on data from clinical trials versus those based on the opinions of experts familiar with
the relevant clinical practice and scientific rationale for such practice (when clinical
trial data are not available). However, these recommendations are not intended to
substitute for the judgment of an expert physician. Management of HIV-related TB
disease is complex, and clinical and public health consequences associated with treat-
ment failure are serious. When possible, treatment of TB among HIV-infected persons
should be directed by, or conducted in consultation with, a physician with extensive
experience in the care of patients with these two diseases.
The objectives of implementing these recommendations are to reduce TB treat-
ment failures, prevent drug-resistant TB, and diminish the adverse effects that TB has
on HIV replication. Moreover, these guidelines contribute to efforts to control and
eliminate TB from the United States by minimizing the likelihood of M. tuberculosis
transmission, which will prevent the occurrence of new cases of TB. Multiple copies of
this report and all updates are available from the Office of Communications, National
TABLE 10. System used to rate the strength of recommendations and the quality of
supporting evidence
Rating
Strength of the recommendation
A Strong; should always be offered
B Moderate; should usually be offered
C Optional
D Should generally not be offered
E Should never be offered
Quality of evidence supporting the recommendation
I At least one randomized trial with clinical endpoints
II Clinical trials with laboratory endpoints only or conducted
 only in populations not infected with human
 immunodeficiency virus
III Expert opinion
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Center for HIV, STD, and TB Prevention, CDC, 1600 Clifton Road, Mail Stop E-06,
Atlanta, GA 30333. The report also is posted on the CDC Division of TB Elimination
Internet website at <http://www.cdc.gov/nchstp/tb> and the MMWR website at
<http://www.cdc.gov/epo/mmwr/mmwr.html>. Readers should consult these sources
regularly for updates in the guidelines.
Active Tuberculosis
Clinical and Public Health Principles
Prompt initiation of effective antituberculosis treatment increases the probability
that a patient with HIV infection who develops TB will be cured of this disease
(45,131 ). TB treatment also quickly renders patients noninfectious (30 ), with the
resulting reduction in the amount of M. tuberculosis transmitted to others, and it mini-
mizes the patient’s risk of death resulting from TB (41–43,132 ). Therefore, clinicians
must immediately and thoroughly investigate the possibility of TB when a patient in-
fected with HIV has symptoms consistent with TB. Persons suspected of having
current TB disease should immediately be started on appropriate treatment, ideally
with directly observed therapy (DOT) (133–135 ), and placed in TB isolation as neces-
sary (136,137 ). Patients with TB and unknown HIV-infection status should be
counseled and offered HIV testing. HIV-infected patients undergoing treatment for TB
should be evaluated for antiretroviral therapy. Most patients with HIV-related TB are
candidates for concurrent administration of antituberculosis and antiretroviral drug
therapies (4 ).
Health-care providers, administrators, and TB controllers must strive to promote
coordinated care for patients with TB and HIV and remove existing barriers to infor-
mation-sharing between TB control programs and HIV/AIDS programs. TB control
programs are responsible for setting TB treatment standards for physicians in the
community, promoting the awareness and use of recommended TB infection-control
practices, and enforcing state and local health department requirements concerning
TB case notification and early reporting of drug-susceptibility test results. Because of
the complexity of managing HIV-related TB disease and the serious public health con-
sequences of mismanagement, care for persons with HIV-related TB should be
provided by, or in consultation with, experts in the management of both TB and HIV
disease.
Diagnosis of HIV-Related Tuberculosis
The typical signs and symptoms of pulmonary TB are cough with or without fever,
night sweats, weight loss, and upper-lobe infiltrates with or without cavitation on
chest x-rays. The diagnosis of TB for some HIV-infected patients might be difficult
because TB in an immunocompromised host can be associated with atypical symp-
toms, a lack of typical symptoms, and a paucity of findings in chest x-rays (138–140 ).
Among persons with AIDS, the diagnosis of TB also can be complicated by the pres-
ence of other pulmonary infections such as Pneumocystis carinii pneumonia and
Mycobacterium avium complex disease and by the occurrence of TB in extrapulmon-
ary sites. For patients with unusual clinical and radiographic findings, the starting
point for diagnosing active TB often is a positive tuberculin skin test (TST). All patients
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with positive TSTs should be evaluated to rule out active TB (see Diagnosis of M. tu-
berculosis Infection Among HIV-Infected Persons).
Medical Evaluation of Patients Suspected of Having Active TB
Rating Recommendation
A.II Every person suspected of having TB should undergo a thorough medical
evaluation (see Box 1).
A.II The evaluation should include HIV counseling and testing unless the per-
son has documentation of a) a positive HIV antibody test or b) a negative
result to an HIV antibody test conducted within the past 6 months.
Management of HIV-Infected Patients with Active TB
Coadministration of TB Treatment and Antiretroviral Therapy
The following management strategies are for patients with HIV-related pulmonary
TB a) who are not known to have or who do not have risk factors for multidrug-
resistant TB and b) for whom antiretroviral therapy is appropriate. When they first
receive care for active TB disease, some patients might already be receiving
antiretroviral therapy, whereas other patients might be newly diagnosed with HIV in-
fection (Figure 1). For these newly diagnosed patients, in addition to the currently
established recommendations for the immediate initiation of antituberculosis therapy,
recently published guidelines (4 ) recommend the use of antiretroviral therapy. When
treatments for HIV and TB disease are begun simultaneously, the optimal setting is
one with experienced and coordinated care givers as well as accessible resources to
provide a continuum of medical services (e.g., a reliable source of medications and
social, psychosocial, and nutritional services).
Patient with active 

















regimen for treatment of TB, and 
evaluate for antiretroviral
therapy within 3 months.
Use rifabutin-based* drug




use streptomycin-based drug 
regimen for treatment of TB, and 
start/continue antiretroviral 
therapy.
*Coadministration of rifabutin with ritonavir, saquinavir (Invirase), or delavirdine is not
recommended.
FIGURE 1. Recommended management strategies for patients with human
immunodeficiency virus (HIV) infection and tuberculosis (TB)
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To receive continuing education credit, please answer all of the following questions:
1. Which of the following statements are true? (Indicate all that are true.)
A. Human immunodeficiency virus (HIV) infection accelerates the natural progres-
sion of tuberculosis (TB).
B. Active TB accelerates the natural progression of HIV infection and disease.
C. The mortality rate for HIV-infected persons with TB is four times greater than
the rate for TB patients not infected with HIV.
D. The toxicity associated with isoniazid TB preventive therapy significantly out-
weighs this therapy’s benefits in preventing active TB in an HIV-infected person.
2. Which of the following strategies are recommended for patients with TB taking
  protease inhibitors for HIV therapy? (Indicate all that are true.)
A. Stop protease inhibitor therapy to allow the use of rifampin for TB treatment.
B. Use an antituberculosis treatment regimen that includes rifabutin instead of
rifampin.
C. Ensure that experienced and coordinated TB/HIV care givers are available.
D. Provide therapy for TB that is directly observed.
3. Which of the following strategies are recommended for HIV-infected patients with
 active TB? (Indicate all that are true.)
A. Immediately and simultaneously begin treatment regimens that include a pro-
tease inhibitor for HIV therapy and drugs other than rifampin for
antituberculosis therapy.
B. Immediately and simultaneously begin treatment regimens that include a pro-
tease inhibitor for HIV therapy and rifampin for antituberculosis therapy.
C. For patients who start antiretroviral therapy with a protease inhibitor, plan a
2-week period between the last dose of rifampin and the first dose of protease
inhibitor.
D. For patients who are not on antiretroviral therapy when TB is diagnosed, plan
to start antiretroviral therapy at the end of the induction phase of TB therapy
(8 weeks) or when TB therapy is completed.
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4. When rifabutin is administered with indinavir, nelfinavir, or amprenavir, the 
 recommended dosage of rifabutin is: (Choose the one correct answer.)
A. 300 mg daily or 150 mg twice weekly.
B. 300 mg daily or 300 mg twice weekly.
C. 150 mg daily or 300 mg twice weekly.
D. 150 mg daily or 150 mg twice weekly.
5. A paradoxical reaction during the course of TB and HIV treatment . . .
 (Indicate all that are true.)
A. is a temporary exacerbation of symptoms and signs of TB in some patients
who have restored immune function because of effective antiretroviral therapy.
B. is always associated with a positive Mycobacterium tuberculosis culture.
C. if suspected, calls for evaluating the patient to rule out other causes of the
signs and symptoms (e.g., antituberculosis treatment failure).
D. might require hospitalization and possibly time-limited use of corticosteroids
(e.g., prednisone therapy) if the patient has severe or life-threatening clinical
manifestations.
6. When administered with rifamycins, which of the following drugs might require a
 dosage adjustment, the use of alternative therapies, or other changes because of






7. Which of the following drugs is not recommended for patients receiving
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8. Which of the following statements are true for HIV-infected persons? (Indicate all
 that are true.)
A. Persons who have a positive tuberculin skin-test reaction (≥5 mm) are candi-
dates for TB preventive therapy.
B. Persons with a negative tuberculin skin-test reaction (<5 mm) are never candi-
dates for TB preventive therapy.
C. For persons with a negative tuberculin skin-test reaction (< 5 mm), a history of
exposure to M. tuberculosis should be investigated and used as the basis for
prescribing TB preventive therapy.
D. Persons with recent contact with an infectious TB patient should receive TB
preventive therapy regardless of age, skin-test results, or history of previous
TB preventive therapy.
9. Which of the following TB preventive therapy options are recommended for HIV-
 infected adults with a positive tuberculin skin-test reaction (≥5 mm), no
 evidence of active TB, and no history of exposure to isoniazid- and rifampin-
 resistant strains of M. tuberculosis? (Indicate all that are true.)
A. Isoniazid daily for 9 months.
B. Rifampin (or rifabutin) and pyrazinamide daily for 2 months.
C. Isoniazid 2 times per week for 9 months.
D. Isoniazid daily 6 months.






E. 25 or more
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11. Please indicate the setting where you work.
A. City/county/state health department
B. Other public health agency




12. How long did it take you to read the report and complete this exam?
A. ≤2 hours
B. >2 hours but <3 hours
C. ≥3 hours but <4 hours
D. ≥4 hours
The following questions will assess your perceptions of the readability and
applicability of the material.
        Answer guide for questions 1–9










13. Overall, this report met
the stated objectives.
A B C D E
14. The tables and figures are
useful.
A B C D E
15. Overall, the presentation
of the report enhanced
my ability to understand
the material.
A B C D E
16. These recommendations
will affect my practice.
A B C D E
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Because of drug interactions, the use of rifampin to treat TB is not recommended
for patients who a) will start treatment with an antiretroviral regimen that includes a
protease inhibitor or a nonnucleoside reverse transcriptase inhibitor (NNRTI) at the
same time they begin treatment for TB (4 ) or b) have established HIV infection that is
being maintained on such an antiretroviral regimen when TB is newly diagnosed and
needs to be treated. Thus, two TB treatment options are currently recommended for
these patients: a) a rifabutin-based regimen or b) an alternative nonrifamycin regimen
that includes streptomycin (see Treatment Options for Patients with HIV Infection and
Drug-Susceptible Pulmonary TB and Figure 1). Using a rifampin-based TB treatment
regimen continues to be recommended for patients with HIV infection a) who have
not started antiretroviral therapy, when both the patient and the clinician agree that
waiting to start such therapy would be prudent or b) for whom antiretroviral manage-
ment does not include a protease inhibitor or an NNRTI (4 ) (Figure 1).
BOX 1. Components of the medical evaluation for human immunodeficiency
virus-infected patients suspected of having tuberculosis
The medical evaluation should include the following questions and assessments:
Medical History
• Ask all patients about their history of tuberculosis (TB) treatment. If the patient has pre-
viously received treatment, care providers must determine the antituberculosis drugs
used, duration of treatment, history of adverse reactions, reasons for discontinuation of
treatment, history of adherence with treatment, and previous antituberculosis drug-
susceptibility test results.
• Question all patients about the following risk factors for drug-resistant TB: a) previous
treatment for TB, especially if it was incomplete; b) previous residence in a country
outside the United States where drug-resistant TB is common; c) close contact with a
person who has drug-resistant TB or multidrug-resistant TB; and d) previous residence
in an institution (i.e., hospital, prison, homeless shelter) with documented transmission
of a drug-resistant strain of TB.
• Ask all patients about their history of antiretroviral therapy and their history of therapies
to prevent opportunistic infections. If the patient has previously or is currently receiving
these treatments, care providers should determine the drugs used, duration of treat-
ment, history of adverse reactions, and reasons for discontinuation of treatment if
treatment ended. 
• Ask female patients whether they might be pregnant. Women of childbearing potential
with menses more than 2 weeks late should receive a pregnancy test. (See TB Treat-
ment for HIV-Infected Pregnant Women.)
• When clinical specimens for culture and susceptibility testing cannot be obtained from
patients (e.g., young children, patients with skeletal or meningeal TB), the culture and
drug-susceptibility results of the Mycobacterium tuberculosis strain isolated from the
infecting source-patient should be investigated and reviewed if available so that TB
treatment for the current patient can be tailored appropriately. (See TB Treatment for
HIV-Infected Children.)
• If necessary, perform a Mantoux-method tuberculin skin test (TST) to help diagnose
culture-negative TB.
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When determining the time to begin antiretroviral therapy for patients who are
acutely ill with TB, clinicians and patients need to consider the existing clinical issues
(e.g., drug interactions and toxicities, ability to adhere to two complex treatment regi-
mens, and laboratory abnormalities). A staggered initiation of antituberculosis and
antiretroviral treatments for patients not currently on antiretroviral therapy might
promote greater adherence to the TB and HIV treatment regimens and reduce the
associated drug toxicity of both regimens. This strategy might include starting
antiretroviral therapy either at the end of the 2-month induction phase of TB therapy
or after TB therapy is completed. When a decision is made to delay initiation of anti-
retroviral therapy, clinicians should monitor the patient’s condition by measuring
BOX 1. Components of the medical evaluation for human immunodeficiency
virus-infected patients suspected of having tuberculosis — Continued
Chest X-Ray Examination
• Perform a chest x-ray examination. HIV-related immunosuppression reduces the inflam-
matory reaction and cavitation of pulmonary lesions, and therefore HIV-infected
patients with pulmonary TB can have atypical findings or normal chest x-rays. Children
younger than age 5 years should undergo both a posterior-anterior and a lateral chest
x-ray. All other persons should receive a posterior-anterior chest x-ray; additional chest
x-ray examinations should be performed at the physician’s discretion. Pregnant women
who are being evaluated for active TB disease should undergo a chest x-ray (with the
appropriate shielding) without delay, even during the first trimester of pregnancy.
Patients suspected of having extrapulmonary TB should undergo a chest x-ray to rule
out pulmonary TB.
Laboratory Tests
• Collect smears for acid-fast bacilli, cultures, and drug susceptibilities from expectorated
or induced sputum samples on 3 consecutive days, preferably in the mornings. Children
who are unable to produce sputum spontaneously or who cannot use the sputum
induction machine should be admitted to the hospital for early morning gastric aspi-
rates on 3 consecutive, separate days.
• Obtain a complete blood cell count, including platelets.
• Conduct chemistry panel tests, especially for liver enzyme levels (serum glutamic
oxalacetic transaminase or aspartate aminotransferase [SGOT/AST] and serum
glutamic pyruvic transaminase or alanine aminotransferase [SGPT/ALT]); total bilirubin;
uric acid; blood urea nitrogen; and creatinine.
Other Procedures
• Perform a baseline visual acuity exam and test for red-green color perception for all
patients who will be receiving ethambutol.
• Perform baseline audiometry tests if an aminoglycoside (e.g, streptomycin, amikacin,
kanamycin) or capreomycin will be administered.
• Perform as necessary procedures such as bronchoscopies and bronchoalveolar lavage;
biopsies and aspirates (e.g, of peripheral lymph nodes, visceral lymph nodes, liver, and
bone marrow); mycobacterial culturing of nonrespiratory clinical specimens (e.g.,
blood, urine, pleural fluid); and radiologic evaluations other than chest x-rays (e.g.,
computerized tomographies, magnetic resonance imaging).
Vol. 47 / No. RR-20 MMWR 27
plasma HIV RNA levels (viral load) and CD4+ T-cell counts and assessing the HIV-
associated clinical condition at least every 3 months (4), because such information
will assist in decisions regarding the timing for initiating such therapy. For some
patients, switching from a rifampin-based TB regimen to either a rifabutin-based or a
nonrifamycin-based TB regimen will be necessary if the decision is made to start anti-
retroviral therapy before completion of antituberculosis therapy. Clinicians and
patients should be aware that the potent effect of rifampin as a CYP450 inducer
(77,80), which lowers the serum concentration of protease inhibitors and NNRTIs, con-
tinues up to at least 2 weeks following the discontinuation of rifampin. Thus, they
should consider planning for a 2-week period between the last dose of rifampin and
the first dose of protease inhibitors or NNRTIs (see TB Drug Interaction and Absorp-
tion and Table 1A of Appendix).
Treatment Options for Patients with HIV Infection and 
Drug-Susceptible Pulmonary TB
A.II DOT and other strategies that promote adherence to therapy should be
used for all patients with HIV-related TB.
A.II For patients who are receiving therapy with protease inhibitors or NNRTIs,
the initial phase of a 6-month TB regimen consists of isoniazid, rifabutin,
pyrazinamide, and ethambutol. These drugs are administered a) daily for
8 weeks or b) daily for at least the first 2 weeks, followed by twice-a-week
dosing for 6 weeks, to complete the 2-month induction phase. The second
phase of treatment consists of isoniazid and rifabutin administered daily or
twice a week for 4 months (see Six-month RFB-based therapy in Table 1A
of Appendix).
B.II For patients for whom the use of rifamycins is limited or contraindicated
for any reason (e.g., intolerance to rifamycins, patient/clinician decision
not to combine antiretroviral therapy with rifabutin), the initial phase of a
9-month TB regimen consists of isoniazid, streptomycin,* pyrazinamide,
and ethambutol administered a) daily for 8 weeks or b) daily for at least the
first 2 weeks, followed by twice-a-week dosing for 6 weeks, to complete
the 2-month induction phase. The second phase of treatment consists
of isoniazid, streptomycin,* and pyrazinamide administered 2–3 times a
week for 7 months (see Nine-month SM-based therapy in Table 1A of
Appendix).
A.I For patients who are not candidates for antiretroviral therapy, or for those
patients for whom a decision is made not to combine the initiation of
antiretroviral therapy with TB therapy, the preferred option continues to be
a 6-month regimen that consists of isoniazid, rifampin, pyrazinamide, and
ethambutol (or streptomycin). These drugs are administered a) daily for
8 weeks or b) daily for at least the first 2 weeks, followed by 2–3-times-per-
week dosing for 6 weeks, to complete the 2-month induction phase. The
*Every effort should be made to continue administering streptomycin for the total duration of
treatment or for at least 4 months after culture conversion (approximately 6–7 months from
the start of treatment). Some experts suggest that in situations in which streptomycin is not
included in the regimen for all of the recommended 9 months, ethambutol should be added
to the regimen to replace streptomycin, and the duration of treatment should be prolonged
from 9 months to 12 months. Alternatives to streptomycin are the injectable drugs amikacin,
kanamycin, and capreomycin.
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second phase of treatment consists of a) isoniazid and rifampin adminis-
tered daily or 2–3 times a week for 4 months. Isoniazid, rifampin,
pyrazinamide, and ethambutol (or streptomycin) also can be administered
three times a week for 6 months (see Six-month RIF-based therapy in Table
1A of Appendix).
D.II TB regimens consisting of isoniazid, ethambutol, and pyrazinamide (i.e.,
three-drug regimens that do not contain a rifamycin, an aminoglycoside
[e.g., streptomycin, amikacin, kanamycin], or capreomycin) should gener-
ally not be used for the treatment of patients with HIV-related TB; if these
regimens are used for the treatment of TB, the minimum duration of
therapy should be 18 months (or 12 months after documented culture
conversion).
A.II Pyridoxine (vitamin B6) (25–50 mg daily or 50–100 mg twice weekly)
should be administered to all HIV-infected patients who are undergoing TB
treatment with isoniazid, to reduce the occurrence of isoniazid-induced
side effects in the central and peripheral nervous system.
E.II Because CDC’s most recent recommendations for the use of antiretroviral
therapy strongly advise against interruptions of therapy,* and because
alternative TB treatments that do not contain rifampin are available, pre-
vious antituberculosis therapy options that involved stopping protease
inhibitor therapy to allow the use of rifampin (Option I and Option II [3 ])
are no longer recommended.
Medications and Doses for Treatment of TB
No rating When rifabutin is used concurrently with indinavir, nelfinavir, or am-
prenavir, the recommended daily dose of rifabutin should be decreased
from 300 mg to 150 mg (Table 2A of Appendix). 
No rating The dose of rifabutin recommended for twice-weekly administration is
300 mg, and this dose recommendation does not change if rifabutin is
used concurrently with indinavir, nelfinavir, or amprenavir (Table 2A of
Appendix).
No rating Preliminary drug interaction studies suggest that when rifabutin is used
concurrently with efavirenz, the dose of rifabutin for both daily and twice-
weekly administration should be increased from 300 mg to 450 mg.
No rating Three-times-per-week administration of rifabutin used in combination with
antiretroviral therapy has not been studied, and thus a recommendation
for adjustment of dosages cannot currently be made.
No rating Experts do not know whether the daily dose of rifabutin should be reduced
when this drug is used concurrently with either soft-gel saquinavir (For-
tovase) or nevirapine.
No rating No modifications in the usually recommended doses of isoniazid, etham-
butol, pyrazinamide, or streptomycin (Table 2A of Appendix) are necessary
if these drugs are used concurrently with protease inhibitors, NNRTIs, or
nucleoside reverse transcriptase inhibitors (NRTIs).
*To minimize the emergence of drug-resistant HIV strains, if any antiretroviral medication must
be temporarily discontinued for any reason, clinicians and patients should be aware of the
theoretical advantage of stopping all antiretroviral agents simultaneously, rather than continu-
ing the administration of one or two of these agents alone (4).
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No rating The safety and effectiveness of rifapentine (Priftin®), a rifamycin newly
approved by the U.S. Food and Drug Administration for the treatment of
pulmonary tuberculosis, have not been established for patients infected
with HIV. Administration of rifapentine to patients with HIV-related TB is
not currently recommended.
Duration of TB Treatment
A.II The minimum duration of short-course rifabutin-containing TB treatment
regimens is 6 months, to complete a) at least 180 doses (one dose per day
for 6 months) or b) 14 induction doses (one dose per day for 2 weeks)
followed by 12 induction doses (two doses per week for 6 weeks) plus
36 continuation doses (two doses per week for 18 weeks) (see Six-month
RFB-based therapy in Table 1A of Appendix).
A.II The minimum duration of short-course rifampin-containing TB treatment
regimens is 6 months, to complete a) at least 180 doses (one dose per day
for 6 months) or b) 14 induction doses (one dose per day for 2 weeks)
followed by 12–18 induction doses (two to three doses per week for
6 weeks) plus 36–54 continuation doses (two to three doses per week for
18 weeks) (see Six-month RIF-based therapy in Table 1A of Appendix).
A.II Three-times-per-week rifampin regimens should consist of at least
78 doses administered over 26 weeks.*
A.II The final decision on the duration of therapy should consider the patient’s
response to treatment. For patients with delayed response to treatment
(see Box 2), the duration of rifamycin-based regimens should be pro-
longed from 6 months to 9 months (or to 4 months after culture con-
version is documented).
A.II The minimum duration of nonrifamycin, streptomycin-based TB treatment
regimens is 9 months, to complete a) at least 60 induction doses (one dose
per day for 2 months) or b) 14 induction doses (one dose per day for
2 weeks) followed by 12–18 induction doses (two to three doses per week
for 6 weeks) plus either 60 continuation doses (two doses per week for
30 weeks) or 90 continuation doses (three doses per week for 30 weeks).
A.II When making the final decision on the duration of therapy, clinicians
should consider the patient’s response to treatment. For patients with
delayed response to treatment (see Box 2), the duration of streptomycin-
based regimens should be prolonged from 9 months to 12 months (or to
6 months after culture conversion is documented).
A.III Interruptions in therapy because of drug toxicity or other reasons should
be taken into consideration when calculating the end-of-therapy date for
individual patients. Completion of therapy is based on total number of
medication doses administered and not on duration of therapy alone.
A.III Reinstitution of therapy for patients with interrupted TB therapy might
require a continuation of the regimen originally prescribed (as long as
needed to complete the recommended duration of the particular regimen)
*Three-times-per-week rifabutin regimens, used in combination with antiretroviral therapy, have
not been studied.
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BOX 2. Components of the monthly medical evaluation for human immuno-
deficiency virus-infected patients undergoing treatment for active tuberculosis
For patients infected with human immunodeficiency virus (HIV) who are undergoing treat-
ment for active tuberculosis (TB), clinicians should include the following components in the
monthly evaluation:
• Once a month, evaluate symptoms and signs of TB (response to treatment) by conduct-
ing a) a physical examination (the nature and extent of this evaluation will depend on
the patient’s symptoms and the site of disease) and b) for patients with pulmonary TB,
an examination by smear and culture of an expectorated or induced sputum specimen
until cultures are no longer positive for Mycobacterium tuberculosis.
• Perform as necessary for individual patients laboratory tests such as: complete blood
cell count, platelet count, and tests for serum glutamic oxalacetic transaminase or
aspartate aminotransferase (SGOT/AST) and serum glutamic pyruvic transaminase or
alanine aminotransferase (SGPT/ALT), alkaline phosphatase, total bilirubin, uric acid,
blood urea nitrogen, and creatinine.
• To assist in the decision about the duration of TB treatment, investigate the possibility
of a delayed response to treatment (Table 1A of Appendix). Delayed response to treat-
ment should be suspected (and in most cases treatment duration should be prolonged)
if by the end of the 2-month induction phase of therapy, patients a) continue to be
culture-positive for M. tuberculosis or b) do not experience resolution of signs or symp-
toms of TB or do experience progression of signs or symptoms of TB (e.g., persistent
fever, progressive weight loss, or increase in size of lymph nodes, abscesses, or other
tuberculous lesions, none of which can be accounted for by a disease other than TB).
(See Duration of TB Treatment.)
• Some factors potentially associated with TB treatment failure are a large mycobacterial
load and extensive lung cavitation at baseline, nonadherence with the drug regimen
(even among patients assumed to be on DOT), inappropriately low medication doses,
and impaired absorption of drugs. Immediately institute corrective measures for those
factors amenable to intervention.
• Because patients with HIV-infection often are treated with multiple drugs in addition to
antituberculosis drugs, at each visit, review all medications that the patient is taking and
assess any change in medications for potential drug interactions with TB medications.
Efforts to manage these potential problems related to drug interactions require the
coordinated efforts of care givers for HIV and TB disease. (See TB Drug Interaction and
Absorption.)
• Because several antituberculosis drugs have hepatotoxicity as a potential side effect
(Table 2A of Appendix), advise all persons taking TB medications about the symptoms
consistent with hepatitis (e.g., anorexia, nausea, vomiting, abdominal pain, jaundice)
and instruct them to discontinue all TB medications immediately and seek medical
attention promptly if they exhibit such symptoms. These patients usually will need an
examination by a physician, liver function tests, and a planned strategy for restarting TB
treatment.
• If ethambutol is administered, perform a monthly visual acuity exam and test for red-
green color perception.
• If streptomycin is administered, perform audiometry and renal function tests as needed.
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or a complete renewal of the regimen. In either situation, when therapy is
resumed after an interruption of ≥2 months, sputum samples (or other
clinical samples as appropriate) should be taken for smear, culture, and
drug-susceptibility testing.
Management of the Coadministration of TB and HIV Therapies, Including the
Potential for Paradoxical Reactions
When antituberculosis treatment has been started, all patients should be
monitored for response to antituberculosis therapy, drug-related toxicity, and drug
interactions. Detailed recommendations for managing antiretroviral therapy are
published elsewhere (4 ), and consultation with experts in this area is highly recom-
mended.
The frequency and type of most TB medication side effects are similar among TB
patients with and without HIV infection (30,65,67 ). When caring for HIV-infected per-
sons, clinicians must be aware of the following problems that can result from the
administration of TB medications: a) patients might have a higher predisposition to-
ward isoniazid-related peripheral neuropathy; b) evaluation of dermatologic reactions
related to TB medications might be complicated because HIV-infected patients are
subject to several dermatologic diseases related to HIV disease or to medications used
for other treatment or prophylaxis reasons; and c) patients undergoing concurrent
therapy with rifabutin and protease inhibitors or NNRTIs are at risk for rifabutin toxic-
ity associated with increased serum concentrations of this drug. The reported adverse
events associated with rifabutin toxicity include arthralgias, uveitis, and leukopenia
(86,101–103 ). Detailed recommendations for managing these adverse reactions are
published elsewhere and should be consulted (2,64 ).
Paradoxical reactions — temporary exacerbation of symptoms, signs, or radio-
graphic manifestations of TB (e.g., recurrence of fever, enlarged lymph nodes,
appearance of cavitation in previously normal chest x-ray) among patients who have
experienced a good clinical and bacteriologic response to antituberculosis therapy —
have been reported among patients coinfected with HIV who have restored immune
function because of antiretroviral therapy (76 ). The synchronization and severity of
paradoxical reactions associated with antiretroviral therapy are not well understood;
therefore, experts do not know whether the occurrence of these reactions should af-
fect the timing of initiating or changing antiretroviral therapy when such therapy is
indicated for a patient with HIV infection. However, because an association between
paradoxical reactions and initiation of antiretroviral therapy has been noted, clinicians
should be aware of this possibility and discuss the risks with patients undergoing ther-
apy for active TB.
Monthly Medical Evaluation and the Diagnosis and Management 
of Paradoxical Reactions
A.II All patients should receive a monthly clinical evaluation (see Box 2) to
monitor their response to treatment, adherence to treatment, and medica-
tion side effects (Table 2A of Appendix). During the early days of therapy,
the interval between these evaluations might be shorter (e.g., every
2 weeks).
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A.II Patients suspected of having paradoxical reactions should be evaluated to
rule out other causes for their clinical presentation (e.g., TB treatment fail-
ure) before attributing their signs and symptoms to a paradoxical reaction.
C.III Some experts recommend that to avoid paradoxical reactions, clinicians
should delay the initiation of or changes in antiretroviral therapy until the
signs and symptoms of TB are well controlled (possibly 4–8 weeks from
the initiation of TB therapy). 
No rating For patients with a paradoxical reaction in whom the symptoms are not
severe or life-threatening, the management of these reactions might
consist of symptomatic therapy and no change in antituberculosis or
antiretroviral therapy. For patients with a paradoxical reaction associated
with severe or life-threatening clinical manifestations (e.g., uncontrollable
fever, airway compromise from enlarging lymph nodes, enlarging serosal
fluid collections [pleuritis, pericarditis, peritonitis], sepsis-like syndrome),
the management might include hospitalization and possibly a time-limited
use of corticosteroids (e.g., prednisone started daily at a dose of 60–80 mg
and reduced after 1 or 2 weeks, with the resolution of symptoms as a
guide; in most cases, corticosteroid therapy should last no more than
4–6 weeks).
TB Drug Interaction and Absorption
E.II Given the expected drug interactions that would result in markedly
decreased serum levels of antiretroviral agents, and given the overlapping
toxicities, the coadministration of rifampin with any of the protease inhibi-
tors or with NNRTIs, as well as the coadministration of rifabutin with
ritonavir, hard-gel saquinavir (Invirase), or delavirdine, is contraindi-
cated.
A.II The potent effect of rifampin as a CYP450 inducer, which lowers the serum
concentration of protease inhibitors and NNRTIs, is expected to continue
up to at least 2 weeks following the discontinuation of rifampin. Therefore,
to diminish the likelihood of adverse effects on drug metabolism,
clinicians should plan the start of therapy with protease inhibitors or
NNRTIs at least 2 weeks after the date of the last dose of rifampin.
A.II Rifabutin is a less potent CYP450 inducer than rifampin and thus can be
used (with adjustments in dosages) concurrently with the NNRTIs nevirap-
ine or efavirenz or with certain protease inhibitors (e.g., indinavir,
nelfinavir, and possibly soft-gel saquinavir [Fortovase] and amprenavir).
No rating Indinavir serum concentrations are decreased by rifabutin-related induc-
tion of the hepatic cytochrome P450; therefore, when indinavir is used in
combination with rifabutin, the dose of indinavir usually is increased from
800 mg every 8 hours to 1,200 mg every 8 hours.
No rating Nelfinavir serum concentrations are also decreased when nelfinavir is
used in combination with rifabutin (Table 1A of Appendix); however, the
resultant metabolite of nelfinavir is known to be active against HIV. Never-
theless, some experts suggest increasing the dose of nelfinavir from
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750 mg three times per day to 1,000 mg three times per day when used in
combination with rifabutin.
No rating Experts do not know whether dose-modifications are needed for soft-gel
saquinavir (Fortovase), amprenavir, nevirapine, or efavirenz if these
agents are used in combination with rifabutin.
No rating Many other medications commonly used by patients with HIV infection
have drug interactions with the rifamycins (rifampin or rifabutin) of suffi-
cient magnitude to require interventions such as dose adjustments or use
of alternative therapies. Some examples of these drugs are hormonal
contraceptives, dapsone, ketoconazole, fluconazole, itraconazole, narcot-
ics (including methadone), anticoagulants, corticosteroids, cardiac glyco-
sides, hypoglycemics (sulfonylureas), diazepam, beta-blockers, anticon-
vulsants, and theophylline.
No rating Malabsorption of antituberculosis drugs has been demonstrated in some
patients with HIV infection, and in some cases, it has been associated with
TB treatment failures and the selection of drug-resistant M. tuberculosis
bacilli (141–145 ). Therapeutic drug monitoring has been advocated by
some experts as an adjunct in the management of HIV-related TB (146 ).
This approach might be useful when evaluating patients with TB treatment
failure or relapse and in the treatment of multidrug-resistant (MDR) TB.
However, the role of therapeutic drug monitoring in the routine manage-
ment of TB among HIV-infected patients has not been established and is
not presently recommended.
Treatment of TB in Special Situations
The following general treatment recommendations address special situations such
as drug-resistant forms of HIV-related TB, TB among HIV-infected pregnant women,
TB among HIV-infected children, and extrapulmonary HIV-related TB. Detailed recom-
mendations for managing these patients are published elsewhere (2,64,147–150 ), and
consultation with experts in these areas is highly recommended.
Treatment of Drug-Resistant TB
A.II TB disease resistant to isoniazid only. The treatment regimen should gen-
erally consist of a rifamycin (rifampin or rifabutin), pyrazinamide, and
ethambutol for the duration of treatment. Intermittent therapy adminis-
tered twice weekly can be used following at least 2 weeks (14 doses) of
daily induction therapy (see Duration of TB Treatment). The recommended
duration of treatment is 6–9 months or 4 months after culture conversion.
Isoniazid is generally stopped when resistance (>1% of bacilli resistant to
1.0 µg/mL of isoniazid) to this drug is discovered; however, when low-level
resistance is discovered (>1% of bacilli resistant to 0.2 µg/mL of isoniazid,
but no resistance to 1.0 µg/mL of isoniazid), some experts suggest continu-
ing to use isoniazid as part of the treatment regimen. Because the
development of acquired rifamycin resistance would result in MDR TB,
clinicians should carefully supervise and manage TB treatment for these
patients.
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A.II TB disease resistant to rifampin only. The 9-month treatment regimen
should generally consist of an initial 2-month phase of isoniazid, strepto-
mycin, pyrazinamide, and ethambutol (see Nine-month SM-based therapy
in Table 1A of Appendix). The second phase of treatment should consist of
isoniazid, streptomycin, and pyrazinamide administered for 7 months. Be-
cause the development of acquired isoniazid resistance would result in
MDR TB, clinicians should carefully supervise and manage TB treatment
for these patients.
A.III Multidrug-resistant TB (resistant to both isoniazid and rifampin).
These patients should be managed by or in consultation with physicians
experienced in the management of MDR TB. Findings from a retrospective
study of patients with MDR TB strongly indicate that early aggressive treat-
ment with appropriate regimens (based on the known or suspected
drug-resistance pattern of the M. tuberculosis isolate) markedly decreases
deaths associated with MDR TB (63,151–153 ). Most drug regimens
currently used to treat MDR TB include an aminoglycoside (e.g., strepto-
mycin, kanamycin, amikacin) or capreomycin, and a fluoroquinolone. The
recommended duration of treatment for MDR TB in HIV-seropositive
patients is 24 months after culture conversion, and posttreatment follow-
up visits to monitor for TB relapse should be conducted every 4 months for
24 months. Because of the serious personal and public health concerns
associated with MDR TB, health departments should always use DOT for
these patients and take whatever steps are needed to ensure their adher-
ence to therapy.
TB Treatment for HIV-Infected Pregnant Women
HIV-infected pregnant women who have a positive M. tuberculosis culture
or who are suspected of having TB disease should be treated without
delay. Choices of TB treatment regimens for HIV-infected pregnant women
are those that include a rifamycin (Table 1A of Appendix). Routine use of
pyrazinamide during pregnancy is recommended by international organi-
zations but has not been recommended in the United States because of
inadequate teratogenicity data (2 ). However, for HIV-infected pregnant
women, the benefits of a TB treatment regimen that includes pyrazinamide
outweigh potential pyrazinamide-related risks to the fetus. Aminogly-
cosides (e.g, streptomycin, kanamycin, amikacin) and capreomycin are
contraindicated for all pregnant women because of potential adverse ef-
fects on the fetus. Considerations for antiretroviral therapy for pregnant
HIV-infected women have been published elsewhere (4 ).
TB Treatment for HIV-Infected Children
HIV-infected children who are suspected of having TB disease should be
treated without delay. For HIV-infected children, even those who are too
young to be evaluated for visual acuity and red-green perception, etham-
butol at a dosage of 15 mg/kg body weight (Table 2A of Appendix) should
generally be included as part of the initial regimen, unless the infecting
strain of M. tuberculosis is known or suspected of being susceptible to
A.III
A.II
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isoniazid and rifampin. If drug-susceptibility results are not available, a
four-drug regimen (e.g., isoniazid, rifamycin, pyrazinamide, and ethambu-
tol) for 2 months, followed by intermittent administration of isoniazid and
a rifamycin for 4 months, is recommended. Considerations for antiretro-
viral therapy for children and adolescents have been published elsewhere
(154 ).
TB Treatment for HIV-Infected Patients with Extrapulmonary TB
The basic principles that support the treatment of pulmonary TB in HIV-
infected patients also apply to extrapulmonary forms of the disease. Most
extrapulmonary forms of TB (including TB meningitis, tuberculous
lymphadenitis, pericardial TB, pleural TB, and disseminated or miliary TB)
are more common among persons with advanced-stage HIV disease
(155,156) than among patients with asymptomatic HIV infection. The drug
regimens and treatment durations that are recommended for treating
pulmonary TB in HIV-infected adults and children (Table 1A of Appendix)
are also recommended for treating most patients with extrapulmonary
disease. However, for certain forms of extrapulmonary disease, such as
meningioma, bone, and joint TB, using a rifamycin-based regimen for at
least 9 months is generally recommended.
Latent M. tuberculosis Infection
Clinical and Public Health Principles
When caring for persons with HIV infection, clinicians should make aggressive
efforts to identify those who also are infected with M. tuberculosis. Because the reli-
ability of the tuberculin skin test (TST) can diminish as the CD4+ T-cell count declines,
TB screening with TST should be performed as soon as possible after HIV infection
is diagnosed. Because the risk of infection and disease with M. tuberculosis is
particularly high among HIV-infected contacts of persons with infectious pulmonary or
laryngeal TB, these persons must be evaluated for TB as soon as possible after learn-
ing of exposure to a patient with infectious TB.
Health-care providers, administrators, and TB controllers must coordinate their
work and establish TB screening initiatives in settings where a) the prevalence of
infection with M. tuberculosis among persons with HIV-infection is expected to
be high and b) referral for medical evaluation and TB preventive therapy can be
accomplished. Such settings include prisons, jails, prenatal-care programs, drug treat-
ment programs, syringe exchange programs, HIV specialty clinics, acute-care
hospitals serving populations at high risk of TB, AIDS patient group residences, some
community-health centers, psychiatric institutions, mental health residences, and
homeless shelters. All HIV counseling and testing sites must have mechanisms in
place to ensure that persons identified with HIV infection receive tuberculin skin test-
ing. TB control programs in jurisdictions that have HIV reporting requirements should
make efforts to ensure that all persons with HIV infection have TSTs.
Because of the complexity of problems associated with active TB disease in HIV-
infected persons, and as part of the efforts to control and eliminate TB in the United
States, all HIV-infected persons identified as latently infected with M. tuberculosis
A.II
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should complete a full recommended course of preventive therapy unless such ther-
apy is contraindicated. Public health programs should take an active role in ensuring
that patients treated in outpatient settings complete TB preventive therapy. In certain
outpatient and institutional settings, directly observed preventive therapy (DOPT)
should be used whenever operationally feasible and when resources permit.
Diagnosis of M. tuberculosis Infection Among HIV-Infected Persons
The Mantoux-method TST, with 5 TU of purified protein derivative, is used to diag-
nose M. tuberculosis infection. A TST reaction size of ≥5 mm of induration is
considered positive (i.e., indicative of M. tuberculosis infection) in persons who are
infected with HIV. Persons with a TST reaction size of <5 mm but with a history of
exposure to TB also could be infected with M. tuberculosis; this possibility should be
investigated (157 ). Whenever M. tuberculosis infection is suspected in a patient, an
evaluation to rule out active TB and assess the need for preventive therapy should be
conducted (see Box 3). This evaluation should include HIV counseling and testing for
persons whose HIV status is unknown but who are at risk for HIV infection.
Tuberculin Skin Testing Among HIV-Infected Persons
A.I As soon as possible after HIV infection is diagnosed, all persons should
receive a TST unless previously tested and found to be TST-positive. 
A.II As soon as possible (ideally within 7 days) after learning of an exposure to
a patient with infectious TB, all HIV-infected persons should be evaluated
for TB and receive a TST, regardless of any previous TST results.
B.III TSTs should be conducted periodically for HIV-infected persons who are
TST-negative on initial evaluation and who belong to populations with a
substantial risk of exposure to M. tuberculosis (e.g., residents of prisons,
jails, or homeless shelters). 
C.III Some experts recommend repeat TSTs for HIV-infected persons who are
TST-negative on initial evaluation and whose immune function is restored
because of effective antiretroviral therapy.
C.I Because results of anergy testing in HIV-infected populations in the United
States do not seem useful to clinicians making decisions about preventive
therapy, anergy testing is no longer recommended as a routine compo-
nent of TB screening among HIV-infected persons (157 ). However, some
experts support the use of anergy testing to help guide individual deci-
sions regarding preventive therapy, and some recommend that a TST be
performed on patients previously classified as anergic if evidence indi-
cates that these patients’ immune systems have responded to therapy
with antiretroviral drugs.
Candidates for TB Preventive Therapy Among HIV-Infected Persons
A.I Persons with a TST reaction size of ≥5 mm who have not previously
received treatment for M. tuberculosis infection should receive TB preven-
tive treatment, regardless of their age.
A.II Persons who have had recent contact with an infectious TB patient should
receive TB preventive treatment, regardless of their age, results of TSTs, or
history of previous TB preventive treatment.
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BOX 3. Components of the baseline medical evaluation for tuberculosis preventive
treatment for patients infected with human immunodeficiency virus
When conducting a medical evaluation to rule out active tuberculosis (TB) and administer
preventive treatment for patients infected with human immunodeficiency virus (HIV), clini-
cians should include the following questions and assessments:
Medical History
• Ask patients about their history of recent close contact with a person who has TB
disease. If the infecting source-patient is known, his or her culture and drug-susceptibil-
ity results should be investigated and reviewed so that the preventive therapy regimen
can be tailored appropriately (see Treatment of Latent M. Tuberculosis  in Special
Situations).
• Assess patients for their risk of increased toxicity associated with the medications used
for TB preventive therapy (e.g., history of excessive alcohol ingestion, liver disease,
hepatitis, chronic use of other medications).
• Assess patients for contraindications to TB preventive therapy (Table 3A of Appendix).
• When persons have previously received TB preventive treatment, determine what
drugs were used, duration of treatment, and any history of adverse reactions (Table 2A
of Appendix) and adherence to preventive therapy.
• Ask patients about their history of antiretroviral therapy and their history of therapies to
prevent opportunistic infections. If a patient has ever received or is receiving any of
these treatments, the care provider must determine the drugs used, duration of treat-
ment, history of adverse reactions, potential for drug interactions with TB medications,
and any reasons for discontinuation of treatment if treatment ended.
Chest X-Ray Examination
• A chest x-ray is indicated for all persons being considered for preventive therapy, to rule
out active pulmonary TB disease. Children younger than 5 years old should undergo
both a posterior-anterior and a lateral chest x-ray. All other individuals should receive a
posterior-anterior chest x-ray only; additional x-rays should be performed at the physi-
cian’s discretion. Pregnant women who have a positive TST or who have negative TST
results but are recent contacts of a person who has infectious TB disease should
undergo a chest x-ray (with appropriate shielding) without delay, even during the first
trimester of pregnancy. 
Laboratory Tests
• Obtain a complete blood cell count, and also obtain a platelet count if the patient will be
treated with a rifamycin (rifampin or rifabutin).
• Conduct chemistry panel tests, especially for liver enzyme levels (serum glutamic ox-
alacetic transaminase or aspartate aminotransferase [SGOT/AST] and serum glutamic
pyruvic transaminase or alanine aminotransferase [SGPT/ALT]) and total bilirubin. In
addition, check uric acid levels if the patient will be treated with pyrazinamide.
• Obtain three consecutive sputum samples for smear, culture, and drug-susceptibility
testing to rule out active TB disease in a) persons who have symptoms that indicate TB
disease (e.g., cough, fever, night sweats, weight loss) and b) persons who have chest
x-ray findings that indicate past, healed TB (e.g., noncalcified fibrotic lesions) and who
have a history of no TB treatment or inadequate TB treatment.
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A.II Persons with a history of prior untreated or inadequately treated past TB
that healed and no history of adequate treatment for TB should receive TB
preventive treatment, regardless of their age or results of TSTs. 
C.III Primary prophylaxis for TST-negative, HIV-infected persons with an on-
going and unavoidable high risk of exposure to M. tuberculosis for the
duration of the exposure time (e.g., residents of prisons, jails, or homeless
shelters in which the current prevalence of TB is high) should be consid-
ered in some situations.
TB Preventive Therapy Regimens, Including Dosage Recommendations
The following recommendations are appropriate for adults with HIV infection who
are likely to have latent M. tuberculosis infection with organisms susceptible to
isoniazid and rifamycins. Updated recommendations for children are not yet available.
Several TB preventive therapy regimens are currently recommended (Table 3A of
Appendix). The TB medications used in these regimens have varying doses, toxicities,
and monitoring requirements (Table 2A of Appendix). All patients on twice-a-week
dosing regimens should receive DOPT; some experts also recommend DOPT for
patients on 2-month preventive therapy regimens. The administration of TB preven-
tive therapy regimens that contain rifampin is contraindicated for patients who take
protease inhibitors or NNRTIs. For these patients, the substitution of rifabutin for
rifampin in preventive therapy regimens is recommended; however, the substitution
of rifapentine for rifampin is not currently recommended because rifapentine’s safety
and effectiveness have not been established for patients infected with HIV.
Recommended Preventive Therapy Regimens for Patients Receiving
Protease Inhibitors or NNRTIs
A.II For HIV-infected adults, a 9-month regimen of isoniazid can be adminis-
tered daily.
B.I For HIV-infected adults, a 9-month regimen of isoniazid can be adminis-
tered twice a week (DOPT should be used with intermittant dosing
regimens).
B.III For HIV-infected adults, a 2-month regimen of rifabutin and pyrazinamide
can be administered daily.
No rating The concurrent administration of rifabutin is contraindicated with ritonavir,
hard-gel saquinavir (Invirase), and delavirdine.
Recommended Preventive Therapy Regimens for Patients Not Receiving
Protease Inhibitors or NNRTIs
A.II For HIV-infected adults, a 9-month regimen of isoniazid can be adminis-
tered daily.
B.I For HIV-infected adults, a 9-month regimen of isoniazid can be adminis-
tered twice a week.
A.I For HIV-infected adults, a 2-month regimen of rifampin and pyrazinamide
can be administered daily.
Duration of TB Preventive Therapy
A.II Daily isoniazid regimens should consist of at least 270 doses to be admin-
istered for 9 months or up to 12 months if interruptions in therapy occur. 
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A.III Twice-a-week isoniazid regimens should consist of at least 76 doses to be
administered for 9 months or up to 12 months if interruptions in therapy
occur.
A.II Daily regimens of rifamycin (rifampin or rifabutin) and pyrazinamide
should consist of at least 60 doses to be administered for 2 months or up
to 3 months if interruptions in therapy occur. 
A.III When calculating the end-of-preventive-therapy date for individual pa-
tients, consider interruptions in therapy because of drug toxicity or other
reasons. Completion of therapy is based on total number of medication
doses administered and not on duration of therapy alone.
A.III When reinstituting therapy for patients with interrupted TB preventive
therapy, clinicians might need to continue the regimen originally pre-
scribed (as long as needed to complete the recommended duration of the
particular regimen) or completely renew the entire regimen. In either situ-
ation, when therapy is restored after an interruption of ≥2 months, a
medical examination to rule out TB disease is indicated.
Monthly Monitoring of Patients During TB Preventive Treatment
A.II All persons undergoing preventive treatment for TB should receive a
monthly clinical evaluation of their adherence to treatment and medication
side effects (see Box 4).
BOX 4. Components of the monthly medical evaluation for human immuno-
deficiency virus-infected patients undergoing preventive treatment for latent
Mycobacterium tuberculosis infection
For patients infected with human immunodeficiency virus (HIV) who are undergoing pre-
ventive treatment for latent Mycobacterium tuberculosis infection, clinicians should include
the following components in the monthly evaluation:
• At every monthly evaluation, review signs and symptoms potentially related to active
tuberculosis (TB) disease as well as signs and symptoms of drug reactions potentially
related to antituberculosis drugs (Table 2A of Appendix).
• At the start of preventive therapy and at each subsequent monthly visit, remind patients
of the need to immediately discontinue preventive therapy and seek prompt medical
attention if signs and symptoms of hepatotoxicity appear (e.g., anorexia, abdominal
pain, nausea, vomiting, change in color of urine and feces, jaundice). 
• Monthly liver function tests are advised only for a) persons whose pretreatment tests
were abnormal (>3 times the upper level of normal); b) persons who are 35 years or
older; and c) patients who are pregnant.
• Patients with HIV infection often are treated with multiple drugs in addition to antituber-
culosis drugs. At each visit, all medications that a patient is taking should be reviewed
and assessed for potential drug interactions with TB medications. Some examples of
these drugs are hormonal contraceptives, ketoconazole, fluconazole, itraconazole, nar-
cotics (including methadone), anticoagulants, corticosteroids, cardiac glycosides, hypo-
glycemics (sulfonylureas), diazepam, beta-blockers, anticonvulsants, and theophylline.
Efforts to manage these potential problems related to drug interactions require the
coordinated efforts of HIV and TB patients’ care givers.
40 MMWR October 30, 1998
Treatment of Latent M. tuberculosis Infection in Special Situations
A.I DOPT should always be used with intermittent dosing regimens.
B.III DOPT also should be used when operationally feasible, especially with
2-month preventive therapy regimens and in some special settings (e.g., in
some institutional settings, in some community outreach programs, and
for some persons who are candidates for preventive therapy because they
are household contacts of patients with TB disease who are receiving
home-based DOT).
A.III For persons who are known to be contacts of patients with isoniazid-
resistant, rifamycin-susceptible TB, a 2-month preventive therapy regimen
of a rifamycin (rifampin or rifabutin) and pyrazinamide is recommended.
For patients with intolerance to pyrazinamide, a 4–6-month regimen of a
rifamycin (rifampin or rifabutin) alone is recommended (158–160 )
(Table 3A of Appendix).
C.III The choices for preventive treatment for persons who are likely to
be infected with a strain of M. tuberculosis resistant to both isoniazid
and rifamycins are published elsewhere (161 ). In general, the recom-
mended preventive therapy regimens for these persons include the use of
a combination of at least two antituberculosis drugs that the infecting
strain is believed to be susceptible to (e.g., ethambutol and pyrazinamide,
levofloxacin and ethambutol). The clinician should review the drug-
susceptibility pattern of the M. tuberculosis strain isolated from the infect-
ing source-patient before choosing a preventive therapy regimen.
A.III For HIV-infected women who are candidates for TB preventive therapy, the
initiation or discontinuation of preventive therapy should not be delayed
on the basis of pregnancy alone, even during the first trimester. A 9-month
regimen of isoniazid administered daily or twice a week is the only recom-
mended option (Table 3A of Appendix).
No rating For HIV-infected children who are candidates for TB preventive therapy, a
12-month regimen of isoniazid administered daily is recommended by the
American Academy of Pediatrics (162 ).
 Follow-up of HIV-Infected Persons Who Have Completed Preventive Therapy
A.II Follow-up care — including chest x-rays and medical evaluations — is not
necessary for patients who complete a course of TB preventive treatment,
unless they develop symptoms of active TB disease or are subsequently
reexposed to a person with infectious TB disease.
Follow-up of HIV-Infected Persons Who Are Candidates for, but Who Do Not Receive,
TB Preventive Therapy
A.III These persons should be assessed periodically (in intervals of <6 months)
for symptoms of active TB as part of their ongoing HIV infection manage-
ment. Clinicians should educate these persons about the symptoms of TB
disease (e.g., cough with or without fever, night sweats, weight loss) and
advise them to seek immediate medical attention if they develop such
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symptoms. If persons present with these symptoms, clinicians should al-
ways include TB disease in the differential diagnosis.
CONCLUSIONS
Implementing TB prevention and control strategies for persons infected with HIV
has always been important and is even more critical now that a larger selection of
new, more potent antiretroviral drugs has enabled clinicians to implement therapies
that improve the health and prolong the lives of HIV-infected persons. These an-
tiretroviral therapeutic strategies often include the use of drugs such as the protease
inhibitors or the nonnucleoside reverse transcriptase inhibitors (NNRTIs), which
because of drug interactions cannot be used concurrently with certain other drugs
(e.g., rifampin). Thus, to improve the diagnosis and management of TB and HIV coin-
fection, TB control programs need to be prepared for the following challenges:
• Ensure that all patients with TB receive HIV counseling and testing either on site
or elsewhere. Patients with latent M. tuberculosis infection who are at risk for HIV
infection also should receive HIV counseling and testing.
• Initiate prompt and effective antituberculosis treatment (ideally with directly
observed therapy) for all patients diagnosed with HIV-related TB.
• Promote optimal antiretroviral therapy for patients with M. tuberculosis and HIV
infection.
• Become knowledgeable about the indications, potential dosing adjustments, and
monitoring requirements of a rifabutin-containing regimen (or an alternative
regimen that does not contain rifamycin) for the treatment of TB in patients who
are undergoing antiretroviral therapy with protease inhibitors or NNRTIs.
• Identify potential risk factors for TB treatment failure or relapse as well as the
potential for paradoxical treatment reactions, and learn how to recognize and
manage these outcomes.
• Follow procedures to ensure early recognition and implementation of effective
treatment for drug-resistant TB.
• Recognize that previous options that involved stopping protease inhibitor ther-
apy to allow the use of rifampin for TB treatment are no longer recommended for
two reasons: a) the most recent guidelines for the use of antiretroviral therapy
advise against interrupting HIV therapy, and b) alternatives for TB therapy that do
not contain rifampin are available.
• Coordinate efforts and establish TB screening initiatives in settings where a) the
prevalence of infection with M. tuberculosis among persons with HIV-infection is
expected to be high and b) referral for medical evaluation and therapy for active
or latent TB is possible. 
• Be aware of changes in options for TB preventive therapy. In addition to recom-
mendations for using 9 months of isoniazid daily or twice a week, new short-
course multidrug regimens (e.g., a 2-month course of a rifamycin such as
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rifabutin or rifampin with pyrazinamide) can be prescribed for HIV-infected
patients with latent M. tuberculosis infection.
When faced with treatment choices, TB controllers and clinicians can use these
recommendations to make informed decisions based on the most current research
results available, keeping in mind that as new antiretroviral and antituberculosis
agents become available, these guidelines will likely change. The aim of these recom-
mendations is to help reduce TB treatment failures, prevent cases of drug-resistant
TB, diminish the adverse effects that TB has on HIV replication, and support efforts to
not only control TB, but to eliminate it from the United States. Future research should
include a) the development of methods for early and accurate diagnosis of M. tuber-
culosis infection in persons coinfected with HIV, b) strategies to help simplify
treatment for active and latent TB and increase adherence to and completion of ther-
apy, and c) basic research to define what host factors protect persons from infection
with M. tuberculosis and HIV and from the development of TB and HIV disease.
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Appendix
Recommended Treatment Options
 for Persons with Human Immunodeficiency Virus-Related
Tuberculosis Infection and Disease 


















TABLE 1A. Treatment regimens for human immunodeficiency virus (HIV)-related tuberculosis (TB)
Rating
Induction Phase Continuation Phase Considerations for
HIV Therapy CommentsDrugs Interval and Duration   Drugs Interval and Duration  









Daily for 2 months
(8 weeks)
or
Daily for 2 weeks and






Daily or 2 times/week
for 4 months (18 weeks)
or
2 times/week for
4 months (18 weeks)




A 20%–25% increase in the dose
of protease inhibitors or NNRTIs
might be necessary.
The patient should be monitored
carefully for RFB drug toxicity
(arthalgia, uveitis, leukopenia) if
RFB is used concurrently with
protease inhibitors or NNRTIs.
Evidence of decreased
antiretroviral drug activity should
be assessed periodically with HIV
RNA levels.
No contraindication exists for the
use of RFB with NRTIs.
If the patient also is taking
indinavir, nelfinavir, or
amprenavir, the daily dose of RFB
is decreased from 300 mg to
150 mg. The twice-weekly dose of
RFB (300 mg) remains unchanged
if the patient is also taking these
protease inhibitors.
If the patient also is taking
efavirenz, the daily or twice
weekly dose of RFB is increased
from 300 mg to 450 mg.
Three-times-a-week
administration of RFB used in
combination with antiretroviral
therapy has not been studied.









Daily for 2 months
(8 weeks)
or










7 months (30 weeks)
or
2–3 times/week for
7 months (30 weeks)
Can be used concurrently with
antiretroviral regimens that
include protease inhibitors, NRTIs,
and NNRTIs.
SM is contraindicated for
pregnant women.
Every effort should be made to
continue administering SM for the
total duration of treatment. When
SM is not used for the
recommended 9 months, EMB
should be added to the regimen
and the treatment duration should
be prolonged from 9 months


































Daily for 2 months
(8 weeks)
or
Daily for 2 weeks and














Daily or 2–3 times/week
for 4 months (18 weeks)
or
2–3 times/week for
4 months (18 weeks)
or
3 times/week for
4 months (18 weeks)
Protease inhibitors or NNRTIs
should not be administered
concurrently with RIF.
NRTIs can be administered
concurrently with RIF.
If appropriate, patients should be
assessed every 3 months to
evaluate the decision to initiate
antiretroviral therapy.
A 2-week “P-450 induction
washout” period may be
necessary between the last dose
of RIF and the first dose of
protease inhibitors or NNRTIs.
SM is contraindicated for
pregnant women.
EMB=ethambutol; INH=isoniazid; PZA=pyrazinamide; RFB=rifabutin; RIF=rifampin; SM=streptomycin.
NNRTI=nonnucleoside reverse transcriptase inhibitor; NRTI=nucleoside reverse transcriptase inhibitor.
* Duration of therapy should be prolonged for patients with delayed response to therapy. Criteria for delayed response should be assessed at the end of the
2-month induction phase and include a) lack of conversion of the Mycobacterium tuberculosis  culture from positive to negative or b) lack of resolution or
progression of signs or symptoms of TB.
† Continue PZA and EMB for the total duration of the induction phase (8 weeks).
§ Continue PZA for the total duration of the induction phase (8 weeks). EMB can be stopped after susceptibility test results indicate Mycobacterium tuberculosis























Adverse Reactions Monitoring Comments
Daily Two times/week* Three times/week*
































































•patient is pregnant or at
high risk for adverse
reactions








• patient has symptoms
of adverse reactions
Hepatitis risk increases







for patients taking PIs or
NNRTIs.

























































































• patient has symptoms
of adverse reactions
Use adjusted daily dose
of RFB,§ and monitor for
decreased antiretroviral
activity and for RFB
toxicity if RFB taken
concurrently with PIs or
NNRTIs.
RFB is contraindicated for
patients taking ritonavir,
saquinavir (Invirase ), or
delavirdine.
Reduces levels of many




















































•patient has symptoms of
adverse reactions
Treat hyperuricemia only
if patient has symptoms.
Might make glucose


























tests of visual acuity and
color vision
Optic neuritis might be




























site might reduce pain.
Maximum dose for
patients ≥60 years is 1.0 g.
EMB=ethambutol; INH=isoniazid; PZA=pyrazinamide; RFB=rifabutin; RIF=rifampin; SM=streptomycin.
NNRTIs=nonnucleoside reverse transcriptase inhibitors; PI=protease inhibitor.
IM=intramuscular; IV=intravenous; PO=by mouth.
* All intermittent dosing should be administered with directly observed therapy.
† The concurrent use of RFB is contraindicated with ritonavir, saquinavir (Invirase), and delavirdine. Information regarding the use of rifabutin with saquinavir
(Fortovase), amprenavir, efavirenz, and nevirapine is limited.
§ Not applicable. If nelfinavir, indinavir, or amprenavir is administered with RFB, blood concentrations of these protease inhibitors decrease. Thus, when RFB
is used concurrently with any of these three drugs, the daily dose of RFB is reduced from 300 mg to 150 mg (the twice-weekly dose of RFB is unchanged,
however).
¶ NA=not applicable. If efavirenz is administered with RFB, blood concentrations of RFB decrease. Thus, when RFB is used concurrently with efavirenz, the


















TABLE 3A. Tuberculosis (TB) preventive therapy regimens for adults with human immunodeficiency virus (HIV) infection
Rating Drug         Interval and Duration       Comments Indications Contraindications
A.II INH Daily for 9 months INH can be administered
concurrently with NRTIs,
protease inhibitors, or NNRTIs.
HIV-infected persons who are
candidates for TB preventive
therapy.
History of an INH-induced
reaction, including hepatic,
skin, or other allergic
reactions, or neuropathy.
B.I INH 2 times/week for 9 months DOPT must be used when
twice-weekly dosing is used.
Known exposure to person
who has INH-resistant TB.





Daily for 2 months
Daily for 2 months
Protease inhibitors or NNRTIs
should not be administered
concurrently with RIF; in this
situation, an alternative is the
use of RFB† and PZA.
HIV-infected persons who are
candidates for TB preventive
therapy.
History of a rifamycin-
induced reaction, including
hepatic, skin, or other allergic
reactions, or
thrombocytopenia.
If RFB is administered, patient
should be monitored carefully





precautions might be needed
when rifamycins are used
(e.g., patients using hormonal
contraceptives must be
advised to use barrier









Chronic severe liver disease.
INH=isoniazid; PZA=pyrazinamide; RFB=rifabutin; RIF=rifampin.
DOPT=directly observed preventive therapy; NNRTI=nonnucleoside reverse transcriptase inhibitor; NRTI=nucleoside reverse transcriptase inhibitor.
* For patients with intolerance to PZA, some experts recommend the use of rifamycin (RIF or RFB) alone for preventive treatment. Most experts agree that
available data support the recommendation that this treatment can be administered for as short a duration as 4 months, although some experts would treat
for 6 months.
† The concurrent use of RFB is contraindicated with ritonavir, hard-gel saquinavir (Invirase), and delavirdine. The information regarding the use of RFB with
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